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Abstract
Natural products are bioactive secondary metabolites produced by living
organisms and are prevalently utilized as pharmaceutical drugs. Marine adapted
organisms are a promising source of new natural products possessing unique
chemical structures and biological activities. By studying the biosynthetic
pathways employed by living organisms to produce natural products, insights into
new strategies to generate molecules to combat disease and overcome drug
resistance may be gained. This thesis study aimed to uncover the biosynthetic
pathway employed by a marine actinomycete, Nocardiopsis sp. CMB-M0232, to
catalyze the assembly of the nocardioazines. These molecules are a group of
2,5-diketopiperazine natural products that feature structurally unique functional
groups. Nocardioazine A, the hypothesized end product of the nocardioazine
biosynthetic pathway, exhibits anticancer activity. Bioinformatics analyses
revealed three biosynthetic gene clusters from Nocardiopsis encoding proteins
with hypothesized roles in nocardioazine A biosynthesis. Two cyclodipeptide
synthases (CDPSs), NozA and NcdA, were biochemically characterized in vivo
and in vitro to reveal that both are substrate specific enzymes that utilize
tryptophan-charged tRNA substrates to catalyze assembly of cyclo(L-Trp-L-Trp),
a proposed precursor of nocardioazines. Fidelity is uncommon amongst
characterized CDPSs, making NozA and NcdA important CDPS family additions.
This study also aimed to characterize NozD and NozE, two cytochrome P450
homologs

with

predicted

roles

as

diketopiperazine-tailoring

enzymes.

Heterologous expression of these enzymes in Streptomyces strains was not able
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to confirm the functions of NozD and NozE but set the stage for future studies to
optimize conditions for probing their roles in nocardioazine A biosynthesis. The
results gathered from this study, along with future work to better understand the
engineering of unique functional groups from Nocardiopsis may provide
opportunities to produce new bioactive molecules.
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Chapter I
Introduction

Marine microorganisms: goldmines of natural products
Modern medicine requires an ongoing search for new, clinically useful
drugs to combat disease and overcome drug resistance. It is estimated that less
than one third of over 30,000 human diseases have treatment options and those
options continue to diminish as antibiotic resistance increases at a faster rate
than the development of new antibiotics (Subramani et al. 2012, Netzker et al.
2015). A promising source of new drugs is natural products, bioactive secondary
metabolites produced by living organisms. These molecules can be utilized as
medicines such as antibacterials, anticancer agents and anti-inflammatory drugs
(Newman and Cragg, 2012).
Primary metabolites are molecules directly involved in the growth,
development, and reproduction of an organism; these include fats, proteins,
carbohydrates and nucleic acids. Natural products are secondary metabolites,
which are not necessary for growth, development or reproduction, but are
commonly used as agents to increase their competitive fitness. For example,
some natural products are utilized as chemical defenses for organisms to adapt
to their environment and survive amongst predators or pathogens (Dias et al.
2012). Organisms, including plants, fungi, algae and bacteria, produce natural
products by way of biosynthesis, enzyme-catalyzed processes where simple
chemical building block substrates are converted into more complex products
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(Dias et al. 2012). Secondary metabolites are generally assembled by
specialized metabolic pathways that utilize intermediates from primary metabolic
processes such as photosynthesis and glycolysis. These biosynthetic pathways
presumably evolved due to selective pressure from biotic and abiotic factors such
as viruses, environmental shifts and radiation, producing new metabolites that
allow organisms to adapt and prolong their existence. Because living organisms
adapt to and overcome a diverse variety of environments and predators, the
secondary metabolites produced tend to be unique to the organism (Dias et al.
2012).
Historically, natural products have been the leading source of new drugs,
offering novel and complex chemical structures that are often too difficult to
produce via traditional synthetic chemistry. The 21st century has presented great
strides in the field of natural product drug discovery due to advances in molecular
biology, bioinformatics and sequencing technologies. These advances provide
fast access to genomic information, identification of biosynthetic pathways and
the necessary tools to utilize this information and facilitate drug discovery (Lane
and Moore, 2011). Interdisciplinary collaborations such as those between
biologists, chemists and engineers are also credited with the expansion of this
field. Networking among experts has resulted in a better understanding of the
biosynthesis of structurally novel, bioactive natural products as well as how that
structure links them to their physiological and ecological roles (Dalisay et al.
2013). Use of these modern approaches has greatly facilitated scientists’ efforts
to study biosynthetic pathways and their products (Giessen and Marahiel, 2012).
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For example, recombinant protein expression, used in the current thesis study,
exploits expression hosts such as E. coli or yeast to study the products of
enzymatic synthesis. This biomolecular approach to synthesis provides an
environmentally friendly alternative to synthetic chemistry by using far less toxic
chemicals, therefore offering a less harmful experimental strategy for scientists
and for the environment (Dias et al. 2012).
Of the many organisms that yield natural products, microorganisms are
the leading producers. An unrivaled number (>70%) of novel compounds have
been derived from actinomycetes, bacteria that are members of the order
Actinomycetales such as the genera Actinomadura, Nocardiopsis, Salinispora
and Stremptomyces (Manivasagan et al. 2014). Most of these compounds were
derived from terrestrial actinomycetes, which were found to be prolific producers
of structurally and chemically diverse metabolites. However, following over four
decades of exploration, terrestrial organisms have been largely exhausted as
sources of new drugs due to repetitive discovery of identical compounds.
Research has now shifted significantly toward marine actinomycetes, which are
found in abundance throughout the ocean, from plant- and sponge-associates to
ocean floor sediments (Dalisay et al. 2013, Manivasagan et al. 2013). Marine
adapted organisms hold great potential as sources of new bioactive compounds
possessing unique chemical structures and biological activities. It is hypothesized
that differences in environmental conditions of marine and terrestrial species may
result in different secondary metabolites in marine organisms compared to those
found in terrestrial organisms. Seventy percent of the Earth’s surface is covered
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in water that may contain approximately one million cells per milliliter, setting the
stage for nearly infinite sources of new, marine microorganisms and natural
products (Subramani et al. 2012, Williams 2009).
Lane and Moore (2011) discussed the concept of the marine natural
product “Dogma” to describe the connection between genes, enzymes and
natural products when studying natural product biosynthetic pathways. Studying
how organisms employ genes and enzymes to produce natural products offers
insight into new ways to combat disease and overcome drug resistance by
providing opportunities to modify existing natural products and discover new
bioactive metabolites (Jensen and Fenical, 2006).

Natural product biosynthetic pathways: the keys to unlocking the potential
of organisms to produce natural products
There are several obstacles faced in marine natural product drug
discovery that have been overcome by advancements in molecular genetics and
analytical tools. For example, despite the known presence of novel bioactive
compounds in marine actinomycetes, their use as drugs is hindered due to the
minimal quantities often produced by the organisms. Modern mass spectrometry
(MS) enables the detection of these miniscule quantities of secondary
metabolites, and offers understanding of molecular formulas and structural
insights. Even with the knowledge of their presence, the isolation of compounds
in reasonable quantities for drug development from the native organisms is highly
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challenging. A historical remedy to this issue has been chemical synthesis, but
synthetic approaches face roadblocks in the case of many natural products due
to their complex chemical structures. A study presented by Long et al. (2005)
represents one of the first examples of gene-based strategies to biosynthesize
cyclic dipeptides, the patellamides, from the cyanobacterium, Prochloron
didemni. The researchers cloned the entire patellamide biosynthetic gene cluster
from P. didemni into a heterologous host, E. coli, biosynthesizing the
petallamides in larger quantities than available from the native producing
organism. They also discovered that upon mutating single genes in the
biosynthetic pathway, several variations of the cyclic-peptide natural products
were synthesized, exploiting what is referred to as combinatorial biosynthesis.
An alternative to in vivo biosynthesis is in vitro biosynthesis, an approach
that exploits enzymes as biocatalysts to generate complex metabolites outside of
a heterologous host. By combining such enzymes with desired precursors in
vitro, studies have been able to achieve total synthesis of many structurally
complex compounds. In addition, in vitro biosynthesis presents the opportunity to
exploit enzymes to decorate existing natural products with new functional groups,
and therefore alter their bioactivity. These types of molecular biology approaches
have allowed us to elucidate the origins of many secondary metabolites, exploit
biosynthetic machinery to produce greater quantities of secondary metabolites
and produce new, bioactive derivatives of known compounds (Gulder and Moore,
2010, Lane and Moore, 2012, Smanski et al. 2012).
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Another obstacle that recent studies have begun to investigate is the
notable difference between the large presence of bioinformatics-predicted
biosynthetic gene clusters from microbial genomes compared to the dramatically
smaller number of secondary metabolites observed under standard laboratory
conditions (Netzker et al. 2015). For example, genome sequencing of the marine
actinomycete Salinispora tropica revealed that almost 10% of its 5-Mbp genome
was predicted to have involvement in the biosynthesis of at least 19 different
types of secondary metabolites. Contrary to this number of compounds capable
of being produced, standard laboratory conditions only yielded four different
classes of secondary metabolites from S. tropica (Gulder and Moore, 2009; Lane
and Moore, 2011). Application of molecular biology techniques, such as gene
elimination mutations, has led to discovery of additional metabolites encoded by
the genome (Lane and Moore, 2011). This observation has been noted among
genomes of many bacteria and fungi, suggesting a wealth of new bioactive
metabolites that are not accessible by standard fermentation conditions in the
laboratory (Challis, 2007, Giessen and Marahiel, 2012).
Several hypotheses exist for the evolutionary maintenance of such energy
consuming secondary metabolic pathways, with roles described in habitat
defense, predator inhibition and as intraspecific signaling molecules. The majority
of secondary metabolic pathways appear to be conditionally expressed, only
turned on under specific environmental conditions (Netzker et al. 2015). This
fine-tuned pathway expression may offer many benefits to the organism. For
example, if secondary metabolite pathways were continually expressed in their
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native environment, neighbors exposed would quickly develop resistance and
therefore defeat the purpose of the metabolites, which are commonly used for
defense.
General fermentation conditions used in laboratories do not typically
trigger production of such compounds. By employing methods such as
combinatorial biosynthesis and heterologous expression, researchers are
beginning to unlock the mechanisms to express these silent gene clusters in
organisms and reveal their potential as significant natural product producers
(Ozaki et al. 2013). Through the coevolution of species and their secondary
metabolites over time, nature may lead us to new, naturally evolved and modified
pathways providing us new metabolites and the means to synthesize altered
metabolites (Dias et al. 2012).

Nocardioazines: structurally unique natural products from a marine
actinomycete
Nocardiopsis sp. CMB-M0232 is a marine actinomycete that was first
isolated from sediment samples collected off the coast of Australia in 2009 by Dr.
Robert J. Capon and co-workers. Capon and his research team discovered that
Nocardiopsis sp. CMB-M0232 produced a plethora of interesting, biomedically
active secondary metabolites (Raju et al. 2010, Raju et al. 2011, Raju et al.
2013). For example, nocardiopsins A-D were isolated from this strain, and are
the only members of the macrolide-pipecolate natural product family discovered
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in over ten years (Raju et al. 2011, Raju et al. 2013). The biosynthetic pathway
responsible for the production of nocardiopsins A-D from Nocardiopsis sp. was
recently elucidated by the Lane group (Bis et al. 2015).
Another novel class of compounds isolated from Nocardiopsis sp. are the
nocardioazines (Figure 1), novel prenylated 2,5-diketopiperazines (DKPs)
(Figure 2) (Raju et al. 2011). DKPs are secondary metabolites known for their
potential

medical

application

as

antibacterials,

antitumor

agents

and

immunosuppressives. Special attention has been placed on 2,5-DKP natural
products due to the large number isolated from microorganisms. DKPs are the
simplest cyclic peptides, formed when two amino acids undergo condensation,
resulting in the formation of two peptide bonds that produce a cyclodipeptide
(CDP) (Figure 2) (Borthwick 2012, Bonnefond et al. 2011, Gondry et al. 2009).
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nocardioazine B

nocardioazine A

Figure 1. 2,5-DKP-derived natural products from Nocardiopsis sp. CMB-M0232
presented in their hypothesized biosynthetic pathway: precursor, intermediate and
product (left to right). Prenyl-derived groups are shown in yellow.
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R1
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H
N

O

N
H

R2

Figure 2. A 2,5-diketopiperazine. These are formed by the condensation of two α-amino
acids, where R1 and R2 represent amino acid R groups.

Nocardiopsis sp. produces three notable DKP natural products when
fermented under high salinity conditions: cyclo(L-Trp-L-Trp) and nocardioazines
A-B (Figure 1). All three compounds share a common apparently tryptophanderived 2,5-DKP core. This leads to the hypothesis that cyclo(L-Trp-L-Trp) is the
precursor, nocardioazine B an intermediate, and nocardioazine A the final
product in the nocardioazine biosynthetic pathway (Figure 1). Many DKP natural
products have been identified, but nocardioazines A-B are unique as the only
known C3-prenylated DKPs from a prokaryote and the only indole-C3-normal
prenylated DKP from any source, suggesting the presence of a unique and novel
biosynthetic pathway from Nocardiopsis sp. Prenyl groups are branched 5carbon structures that are of considerable interest because of their prevalence
amongst bioactive natural products (Raju et al. 2011). The unique prenylation of
the nocardioazines strongly suggests that novel enzyme(s) carry out this
biosynthetic transformation.
Furthermore, Dr. Capon’s lab discovered that nocardioazine A functions
as an anticancer agent (Raju et al. 2011). Many cancer cell lines become
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resistant to antitumor agents by overexpressing the ABC transporter, Pglycoprotein (P-gp), which allows cells to eject the drug. Capon’s group found
that nocardioazine A reverses drug resistance in colon cancer cells by acting as
a noncytotoxic inhibitor of P-gp, preventing drugs from leaving the cell.
Nocardioazine A proved to work as effectively as verapamil, a synthetic P-gp
inhibitor (Raju et al. 2011).
The objective of this thesis study was to identify and characterize selected
genes and corresponding enzymes involved in the biosynthesis of nocardioazine
A from Nocardiopsis sp. CMB-M0232. Bioinformatics was used to identify
candidate biosynthetic gene clusters with predicted roles in nocardioazine
assembly. Selected genes within the clusters were characterized through
heterologous expression and profiling of metabolites produced in vivo, as well as
in vitro assays with purified pathway enzymes. These experiments established
the enzymatic basis for assembly of cyclo(L-Trp-L-Trp) as the precursor of
nocardioazine A-B and provided additional candidate biosynthetic enzymes for
characterization in future studies.
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Chapter II
Characterization of two cyclodipeptide synthases from
Nocardiopsis sp. CMB-M0232

Introduction
An impressive number of naturally occurring, structurally diverse DKPs
have been discovered, but their biosynthetic pathways often remain poorly
understood (Giessen and Marahiel, 2014).

For years, a class of enzymes

referred to as nonribosomal peptide synthetases (NRPSs) were recognized as
catalysts for DKP assembly. NRPSs are highly studied, relatively massive (>100kDa) multimodular enzymes organized so that each module is involved in a
single stage of synthesis beginning with a single amino acid modified one step at
a time to produce a final peptide product. NRPSs are responsible for
biosynthesis of the cyclized amino acid core of DKPs via direct, dedicated DKPyielding NRPSs or by prematurely releasing a DKP intermediate from the NRPS
assembly line for a more complex peptide natural product (Giessen et al. 2013).
In 2009, a new class of enzymes referred to as cyclodipeptide synthases
(CDPSs) were first reported to also produce DKPs. CDPSs are unique in their
small size (~30-kDa) relative to massive NRPSs that produce analogous
molecules. Further, CDPSs use a mechanism that is distinct from what is used
by NRPSs to form the peptide bond between two amino acids. This recently
discovered family of enzymes does not employ several modules to activate and
incorporate free amino acids.

Instead, CDPSs ‘hijack’ aminoacyl-tRNAs (aa-
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tRNAs) from the ribosomal machinery in primary metabolism to directly catalyze
formation of peptide bonds to yield 2,5-DKPs (Figure 3) (Gondry et al. 2009,
Belin et al. 2014, Moutiez et al. 2014). By using aa-tRNAs as substrates, CDPSs
bypass the amino acid activation step that NRPSs use and instead redirect
amino acids away from the ribosome, linking primary and secondary metabolism
(Giessen and Marahiel, 2012, Bonnefond et al. 2011, Giessen and Marahiel,
2014).

R

2

CDPS

R1

O

aminoacyl-tRNA

H
N

O

N
H

R2

2,5-DKP

Figure 3. CDPSs are a relatively newly described enzyme family that employs
aminoacyl-tRNAs as substrates for 2,5-DKP assembly. R refers to an amino acid R
group.

To date, over 150 putative CDPS enzymes are logged in the GenBank
database, but less than 12 have been biochemically characterized (Giessen and
Marahiel, 2014). Thus, much remains to be known about this apparently common
biosynthetic enzyme class. Protein sequence comparisons of biochemically
characterized CDPSs reveal varying degrees of identity ranging from 19-70%;
only 8 residues are conserved across all functionally characterized CDPSs and
no consensus sequences are noted for these enzymes (Figure 5). Despite
variation in protein sequences, x-ray structures of the three crystallized CDPSs
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superimpose relatively well, providing evidence for conserved amino acid
residues appearing in the active site and playing critical roles in the substrate
specificity of the enzymes. CDPSs generally exhibit promiscuity with regard to
aa-tRNA substrates, and most produce several 2,5-DKP products. Although most
CDPSs can produce several DKPs, they tend to preferentially synthesize a single
DKP over other products. Single point mutations in albC from Streptomyces
noursei were sufficient to alter the specificity of the enzyme and revealed the
one-at-a-time incorporation of aminoacyl charged-tRNAs in the active site
(Moutiez et al. 2014). Moutiez et al. (2014) also recently unveiled the process of
how CDPSs catalyze reactions with aa-tRNA substrates using as a sequential
ping-pong mechanism (Figure 4).
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Figure 4. Overview of the mechanism employed by cyclodipeptide synthases to catalyze
the production of DKPs. (a) Activated aa-tRNA’s are sequestered from primary
metabolism. (b) Binding of the first aminoacyl moiety from an aa-tRNA to the CDPS’s
serine active site. (c) The first aminoacyl group forms a peptide bond with an aminoacyl
moiety from a second aa-tRNA substrate. (d) The resulting dipeptidyl intermediate
undergoes intramolecular peptide bond formation to close the DKP ring and releases it
from the active site.

Generally,

prokaryotic

CDPSs

produce

DKPs

that

incorporate

phenylalanine, leucine, tyrosine and/or methionine. Only one CDPS from
eukaryotic origin has been identified and that CDPS, Nvec_CDPS2, is able to
incorporate the same four amino acids as well as tryptophan. DKPs that
incorporate tryptophan are recognized as promising bioactive metabolites and
are relatively common molecules despite the scarce number of identified CDPSs
that incorporate tryptophan. Thus, this has left open the question of how living
things yield the wealth of observed Trp-containing DKPs. Recently, Giessen et al.
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(2013) characterized Amir_4627, a CDPS from Actinosynnema mirum, and found
this enzyme as the first to catalyze the production of cyclo(L-Trp-L-Trp). This
discovery also provided the first substrate specific CDPS and the first CDPS
identified from prokaryotic origin to catalyze formation of a Trp-containing DKP.
In this chapter we aim to identify biosynthetic genes and corresponding
enzymes from the draft genome of Nocardiopsis sp. CMB-M0232 with
hypothesized roles in the first step of nocardioazine A biosynthesis, the catalysis
of cyclo(L-Trp-L-Trp) assembly. It is understood that genes involved in the
production of a specific secondary metabolite are generally clustered in the
genomes of bacteria; this facilitates the identification of biosynthetic pathways
(Giessen and Marahiel, 2012). By identifying the enzyme(s) responsible for the
production of cyclo(L-Trp-L-Trp), we may locate other genes involved in
nocardioazine A biosynthesis nearby and thus gain access to the entire
biosynthetic pathway.

Methods
Genome sequencing and bioinformatics analyses of Nocardiopsis sp. draft
genome

to

locate

candidate

enzymes

from

the

nocardioazine

A

biosynthetic pathway
A clone library of Nocardiopsis sp. CMB-M0232 genomic DNA was
created according to procedures described in Bis et al. (2015). Sequencing of
Nocardiopsis sp. CMB-M0232 gDNA was performed by Cofactor Genomics (St.
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Louis, MO) using Illumina with paired-end 80 bp reads and 454 with single end
400 bp reads. BLASTP was used to analyze ORFs for homology to nonribosomal
peptide synthases and cyclodipeptide synthases, putative enzymes in cyclo(LTrp-L-Trp) biosynthesis. Geneious Bioinformatics Software (Biomatters) and
BLASTP were used to compare protein sequence homology between CDPSs
(ClustalW). The phylogenetic tree was created using Geneious Treebuilder with
no outgroup.

Generation of constructs for recombinant expression of Nocardiopsis sp.
CDPS genes, nozA and ncdA, in E. coli
The genes encoding NozA and NcdA from Nocardiopsis sp. draft genome
sequence contig 557 and contig 96, respectively, were codon optimized for
expression in E. coli and were cloned into the pMA-T vector by GeneArt (Life
Technologies) (Appendix A-B). The pMA-T/nozA and pMA-T/ncdA constructs
were introduced into E. coli JM109 by heat shock (Green and Sambrook, 2012).
Isolated colonies were used to inoculate LB media (10 g/L peptone, 5 g/L yeast
extract, 10 g/L sodium chloride) supplemented with ampicillin (100 µg/mL) and
were cultured at 37 °C and 200 rpm overnight. Plasmid DNA was purified from
the cultures using a Qiagen Miniprep Kit and isolated DNA was then digested in
a reaction mixture containing 1.0 µL (~1 µg) of the purified plasmid DNA (pMAT/nozA or pMA-T/ncdA), 4.0 µL of 10X Thermo FastDigest Green Buffer, 2.0 µL
of restriction enzymes (Thermo Scientific) and 31.0 µL of molecular biology grade
water to prepare the CDPS genes for ligation into expression vectors. For
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purposes of in vivo characterization of enzyme function, both nozA and ncdA
were introduced into pQE30 expression vectors and E. coli M15[pREP4] via
protocols that follow. The expression of NcdA was too low in pQE30 for the in
vitro experiments, so the following methods were used to instead introduce ncdA
into pET30a(+) expression vector and E. coli BL21 (DE3).
The pMA-T/nozA was digested with SacI and HindIII and pMA-T/ncdA was
digested with Ndel and HindIII. The reactions were incubated at 37 °C for 1 hour
followed by heat inactivation at 70 °C for 10 minutes. Expression vectors, pQE30
(Qiagen) and pET30a(+) (Novagen), were digested in reactions containing 22 µL
of molecular biology grade water, 4 µL of 10X FastDigest Green Buffer, 10 µL
(~1 ug) of purified plasmid (pQE30 or pET30a(+)) and 2 of µL of each restriction
enzyme.

The reactions incubated at 37 °C for 45 minutes followed by heat

inactivation at 70 °C for 10 minutes. The digests were purified using the Qiagen
QIAquick PCR Cleanup Kit and then subjected to dephosphorylation in reactions
containing 20 µL of molecular biology grade water, 4 µL of Alkaline Phosphatase
10X Buffer (Promega), 15 µL (~15 µg) of restriction digested vector and 1 µL of
Calf Intestinal Alkaline Phosphatase (Promega). The reactions were incubated
at 37 °C for 1 hour followed by heat inactivation at 70 °C for 15 minutes. Digested
CDPSs and expression vectors were verified by agarose gel electrophoresis and
the appropriate sized DNA fragments were cut from the gels and purified using
the Qiagen QIAquick Gel Extraction Kit.
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A ligation reaction to anneal the synthetic nozA gene with pQE30
contained 50 ng of digested pQE30, 37.5 ng of NozA insert DNA, 0.5 µL of 10X
T4 DNA Ligase Buffer (Thermo Scientific), 0.5 µL of T4 DNA Ligase (Thermo
Scientific) and sufficient molecular biology grade water to yield a final volume of 5
µL. The ligations were incubated overnight at 4 °C. The same reaction was set
up to ligate the synthetic ncdA gene with the pET30a(+). The pQE30/nozA
construct was propagated in E. coli JM109 and transformed into E. coli
M15[pREP4] cells using standard heat shock methods (Green and Sambrook,
2012). The pET30a(+)/ncdA construct was propagated in E. coli JM109 and then
transformed into E. coli BL21 (DE3) via heat shock. The constructs were
confirmed by DNA sequencing (Operon). As no biosynthetic gene controls, E.
coli M15[pREP4] and E. coli BL21 (DE3) were transformed with pQE30 and
pET30a(+) plasmid vector, respectively.

In vivo characterization of functions of NozA and NcdA
The pQE30/nozA construct in E. coli M15[pREP4] was cultured in 10 mL
LB broth supplemented with ampicillin (100 µg/mL) and kanamycin (25 µg/mL).
The pET30a(+)/ncdA construct in E. coli BL21 (DE3) was cultured in 10 mL LB
broth supplemented with kanamycin (25 µg/mL). Control E. coli M15[pREP4]
pQE30 and E. coli BL21 (DE3) pET30a(+) containing no biosynthetic genes were
cultured equivalently to treatments.

All treatment and control cultures were

incubated at 37 °C and 200 rpm until an optical density (OD600) of 0.4 was

	
   18	
  

reached. Aliquots of each culture (500 µL) were taken to analyze protein
expression prior to induction. The remaining ~9.5 mL cultures were induced with
a final concentration of 1 mM IPTG and were incubated at 19 °C and 240 rpm for
an additional 19 hours. Following incubation, aliquots of each culture (500 µL)
were taken to analyze protein expression following induction. The remaining ~9.0
mL cultures were centrifuged at 6,000 rpm for 10 minute and the supernatants
were set aside for metabolite profiling by HPLC (described below).
Cell pellets (corresponding to 500 µL culture volume) taken before and
after induction with IPTG were subjected to -80 °C for 1 hour to facilitate cell lysis
and then resuspended in 200 µL of B-PER (Bacterial Protein Extraction Reagent,
Thermo Scientific) with lysozyme (1 mg/mL). The homogenates were incubated
in a 30 °C water bath for 30 minutes and then centrifuged at 13,000 rpm for 6
minutes. Supernatant (20 µL) from each sample was combined with 4X LDS
Non-Reducing Sample Buffer (Thermo Scientific) and subjected to SDS-PAGE to
evaluate expression of recombinant NozA and NcdA.
For analysis of the DKP metabolite profiles from treatment and control
cultures, supernatants (~9 mL) were filter sterilized (0.2 uM cellulose acetate
membrane) into a scintillation vial and dried using a speedvac concentrator
(Savant ISS1100, Thermo Scientific) overnight. The dried supernatants were
resuspended in 500 µL MilliQ water and were transferred to HPLC vials. HPLC
was conducted using an Aligent 1100 HPLC system with a ZORBAX SB-C18
column (4.6 x 150 mm, particle size: 5 µm, pore size of 110 Å). A flow rate of 0.6
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mL/min was used, with solvent A consisting of MilliQ water, solvent C consisting
of acetonitrile and a linear gradient of 0 to 95% solvent C over 50 minutes
following a 3 minute hold at 100 % solvent A. Synthetic cyclo(L-Trp-L-Trp) (0.2
mg/mL) was run as a positive control and provided by Alqahtani et al. (2015).
Metabolite profiles were compared using ChemStation (Agilent).

Site directed mutagenesis of NozA at residues conserved among NozA,
NcdA and Amir_4627
NozA was mutated at several residues unique to L-tryptophan-specific
CDPSs to determine whether the residues played a role in catalysis of cyclo(LTrp-L-Trp) formation. Six primer sets were designed with the goal of yielding
single and double amino acid point mutations (S36A, L131R, S198L, N114R,
N114A, V111R+N114A) by PCR mutagenesis. The PCRs contained 17.9 of µL
molecular biology grade water, 0.1 µL of each forward and reverse primer
(Appendix C, SDM_Mutant_F/R) (0.5 µM final concentration), 5 µL of 5X Phusion
GC Buffer (Thermo Scientific), 0.5 µL of High Fidelity dNTPs (Roche, 10 mM final
concentration), 0.75 µL of DMSO, 0.5 µL of template gDNA (0.4 µg)
(pQE30/nozA) and 0.125 µL of Phusion DNA Polymerase (Thermo Scientific).
The PCRs ran for an initial denaturation of 98 °C for 30 s, 25 cycles of 98 °C for
10 s and 72 °C for 60 s, and a final extension of 72 °C for 5 min with a hold at 4
°C. The PCR products were verified for size (4.1 Kb) by agarose gel
electrophoresis and the appropriate sized DNA fragments were cut from the gels
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and purified using the Qiagen QIAquick Gel Extraction Kit.

The mutated

constructs were ligated on themselves in a reaction containing 2.5 µL (~50 ng) of
the gel purified constructs, 3 µL of 2X DNA ligase buffer and 0.5 µL of T4 DNA
ligase (Thermo Scientific) and were incubated at 25 °C for 8 min. The cyclized
constructs were introduced into E. coli JM109 for propagation, purified by
miniprep and then transformed into E. coli M15[pREP4] by heat shock (Green
and Sambrook, 2012) and incubated on LB agar with ampicillin (100 µg/mL) and
kanamycin (25 µg/mL) at 37 °C overnight. The pQE30 vector containing no
biosynthetic genes served as the negative control and pQE30/nozA served as
the positive control.
Control constructs were transformed in E. coli M15[pREP4] and were
treated identically to the mutated constructs in E. coli M15[pREP4]. In order to
run duplicate experiments, two colonies from each agar plate (E. coli
M15[pREP4]

pQE30/nozA-S36A,

-L131R,

-S198L,

-N114R,

-N114A,

-

V111R+N114A and controls) were inoculated in 10 mL LB broth with ampicillin
(100 µg/mL) and kanamycin (25 µg/mL) and were incubated at 37 °C and 200
rpm until an optical density (OD600) of 0.4 was reached. The cultures were
induced with a final concentration of 1 mM IPTG and were incubated for an
additional 20 hours at 19 °C and 240 rpm. Following incubation, the optical
density (OD600) was measured to ensure the site directed mutations did not
interfere with E. coli growth. The cultures were centrifuged at 6,000 rpm for 10
minutes and the supernatants were filtered through a 0.2 µM cellulose acetate
membrane. For LC/MS analysis, 450 µL of the supernatants were combined with
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50 µL of a synthetic cyclo-3-methyl-L-Trp-N1’-methyl-L-Trp DKP internal
standard synthesized by Alqahtani et al. (2015). The remaining supernatants
were dried using a speedvac concentrator (Savant ISS1100, Thermo Scientific)
overnight, resolubilized in 500 µL MilliQ water and subjected to analytical HPLC
as described above.

Expression and purification of NozA
From an overnight culture of E. coli M15[pREP4] transformed with
pQE30/nozA, 1 mL was used to inoculate 500 mL LB medium supplemented with
ampicillin (100 µg/mL) and kanamycin (25 µg/mL). The culture was incubated for
4 hours at 37 °C and 200 rpm until an optical density (OD600) of ~0.4 was
reached. The culture was induced with a final concentration of 1 mM IPTG and
incubated for an additional 16 hours at 16 °C and 240 rpm. Cells were harvested
by centrifugation (6,000 rpm, 4°C), resuspended in 16 mL lysis buffer (100 mM
Tris HCl, 150 mM NaCl, 5% glycerol, 2 mM DTT, pH 8) and lysozyme (20 mg)
and were incubated at -20 °C and 200 rpm for 30 minutes. Following incubation,
the suspension was sonicated (Branson Digital Sonifier) at 60% amplitude for 2
minutes (1 s pulse:10 s rest). Cell debris was removed by centrifugation (12,000
rpm, 4 °C) and the soluble lysate was filtered through a 0.45 µM cellulose acetate
membrane (Corning). The lysate, containing soluble proteins, was combined with
3 mL of HisPur Ni-NTA Resin (Thermo Scientific), spiked with a final
concentration of 5 mM imidazole and incubated at 4 °C and 200 rpm for 30
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minutes. Lysis buffer with increasing concentrations of imidazole (10 mM, 50
mM, 200 mM and 500 mM) was run through the column and collected. A sample
(20 µL) of each Ni-column fraction was combined with 3 µL 4X LDS NonReducing Sample Buffer (Thermo Scientific), boiled briefly and loaded into a 12%
Precise Protein Gel (Thermo Scientific) along with PageRuler Plus Prestained
Protein Ladder (Life Technologies). The gel was stained with Imperial Protein
Stain (Thermo Scientific) for 30 minutes and destained in Milli-Q water. The Nicolumn fractions containing NozA (~28-kDa) were concentrated using an Amicon
Ultra Centrifugal Filter Device with a 10,000 MWCO (Millipore) to a final volume
of 500 µL and resuspended in 5 mL Buffer A (100 mM Tris HCl, 50 mM NaCl, 5%
glycerol, 2 mM DTT, pH 8) for further purification via FPLC. The sample was
loaded onto a HiTrap Q FF. (5x5 mL) anion exchange column (GE Healthcare)
that was pre-equilibriated with buffer A and the protein was eluted with a gradient
of 0 to 100% buffer B (100 mM Tris HCl, 1 M NaCl, 5% glycerol, 2 mM DTT, pH
8) for 50 mL at a rate of 1 mL/min. Protein elution was monitored at 280 nm and
all fractions containing detectable protein were analyzed via SDS-PAGE as
described

previously.

The

fractions

containing

NozA

(~28-kDa)

were

concentrated and the buffer was exchanged to assay buffer (50 mM Tris HCl,
300 mM NaCl, pH 8) using an Amicon Ultra Centrifugal Filter Device with a
10,000 MWCO. The purified protein was stored on ice while in vitro assays were
prepared.
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Expression and purification of NcdA
A -80 °C freezer stock of E. coli BL21 (DE3) transformed with
pET30a(+)/ncdA was streaked onto LB agar supplemented with kanamycin (25
µg/mL) and incubated overnight at 37 °C. LB media (5 mL) supplemented with
kanamycin (25 µg/mL) was inoculated with an isolated colony and grown at 37 °C
and 200 rpm for ~4 hours. Following incubation, 1 L of LB broth with kanamycin
was inoculated with 1 mL of this starter culture and grown at 37 °C and 200 rpm
until an optical density (OD600) of ~0.4 was reached. The culture was induced
with a final concentration of 1 mM IPTG and incubated for an additional 16 hours
at 19 °C and 240 rpm. The cells were harvested by centrifugation (6,000 rpm,
4°C) and were resuspended in 30 mL lysis buffer with lysozyme (37.5 mg). The
30 mL suspension was split between two 50 mL falcon tubes and each aliquot
(15 mL) was sonicated at 60% amplitude for 2 minutes (1 s pulse:10 s rest) on
ice. Cell debris was removed by centrifugation (12,000 rpm, 4 °C) and the soluble
lysate was filtered through a 0.45 µM cellulose acetate membrane (Corning).
The lysate was combined with 3mL HisPur Ni-NTA Resin (Thermo Scientific),
spiked with a final concentration of 5 mM imidazole and incubated at 4 °C and
200 rpm for 30 minutes. Lysis buffer with increasing concentrations of imidazole
(10 mM, 50 mM, 100 mM x 2, 200 mM x 2 and 500 mM) was run through the
column and collected. An aliquot of each Ni-column fraction was analyzed by
SDS-PAGE as described previously. The Ni-column fractions containing NcdA
(~29-kDa) were concentrated using an Amicon Ultra Centrifugal Filter Device
with a 10,000 MWCO (Millipore) to a final volume of 500 µL and resuspended in
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5 mL Buffer A (100 mM Tris HCl, 50 mM NaCl, 5% glycerol, 2 mM DTT, pH 7.5)
for further purification via fast protein liquid chromatography (FPLC). The sample
was loaded onto a HiTrap Q FF. (5x5 mL) anion exchange column (GE
Healthcare) pre-equilibriated with buffer A and the protein was eluted with a
gradient of 0 to 30% buffer B (100 mM Tris HCl, 1 M NaCl, 5% glycerol, 2 mM
DTT, pH 7.5) for 50 mL at a rate of 1 mL/min. Protein elution was monitored at
280 nm and all fractions containing detectable protein were analyzed via SDSPAGE gel as described previously. The fractions containing NcdA (~29 kDa)
were concentrated and the buffer was exchanged to assay buffer (50 mM Tris
HCl, 300 mM NaCl, pH 8) using an Amicon Ultra Centrifugal Filter Device with a
10,000 MWCO. The purified protein was stored in 1 mM TCEP and 5% glycerol
at -80 °C until in vitro enzyme assays.

In vitro characterization of NozA and NcdA functions and substrate
specificity
To evaluate the function and substrate specificity of the Nocardiopsis
CDPSs in vitro, 100 µL assays containing purified recombinant NozA and NcdA
were incubated with tRNA from E. coli (50 µM, Sigma-Aldrich), E. coli aminoacyltRNA synthetase mix from E. coli (250 units, Sigma, Aldrich), L-Tryptophan (1
mM), ATP (5 mM), MgCl2 (10 mM), KCl (30 mM) and DTT (2 mM) in Tris buffer
(50 mM Tris HCl, 300 mM NaCl, pH 8). Control assays that (1) lacked enzyme,
(2) lacked amino acids, (3) lacked tRNA and/or (4) lacked aminoacyl-tRNA
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synthetase mix were run alongside treatments. All assays were set up at least in
duplicate. All assay components other than the CDPS enzyme were preincubated at 37 °C for 20 minutes to allow charging of the tRNA with tryptophan.
NozA assays were set up the same day as purification, so the enzyme was
added to the pre-incubated assay directly following purification. Purified NcdA
was thawed from -80 °C by incubation in 30 °C water prior to addition to assays.
To evaluate substrate specificity of NozA and NcdA, in vitro assays
identical to those described above were designed with alternative aromatic amino
acids (L-phenylalanine and L-tyrosine, 1 mM). Treatment and control assays
were incubated overnight at 37 °C.
The reactions were stopped by the addition of 5 µL of trichloroacetic acid
(100% w/v) and centrifugation at 13,000 rpm for 30 minutes to precipitate all
proteins. The supernatants (90 µL) were transferred to HPLC vials and combined
with 10 µL of methyl-cyclo(L-Trp-L-Trp) (1 µM), which served as an internal
standard for quantification via HPLC and LC/MS as described previously.

Results and Discussion
Nocardioazine biosynthetic gene clusters hypothesized via bioinformatics
analyses of Nocardiopsis sp. draft genome
Sequencing of Nocardiopsis sp. CMB-M0232 genomic DNA yielded a ~6.4
Mbp draft of the genome, from which over ~5500 open reading frames (ORFs)

	
   26	
  

were predicted using GeneMark (Besemer et al. 2001). These included 11
putative biosynthetic gene clusters, as predicted by AntiSmash (Weber et al.
2015). Analysis of the putative biosynthetic gene clusters by Basic Local
Alignment Search Tool for proteins (BLASTP) revealed two candidate ORFs with
similarity to nonribosomal peptide synthetases (NRPSs) and two with similarity to
cyclodipeptide synthases (CDPSs). Both classes of enzymes have been
previously found to be capable of catalyzing the formation of the DKP
backbones, suggesting these enzymes might play roles in assembly of the
predicted cyclo(L-Trp-L-Trp) precursor leading to nocardioazines A-B (Figure 2).
Further bioinformatics analyses of the adenylation domains from the putative
NRPSs revealed that none of the NRPSs were likely to incorporate two
tryptophan substrates. Additionally, genes identified upstream and downstream
from the putative NRPS are similar to those found in a hybrid polyketide
synthase-nonribosomal peptide synthetase biosynthetic pathway known to
produce natural products other than prenylated diketopiperazines. Outside the
scope of this thesis, one of these NRPSs was found to play a role in nocardiopsin
assembly (Bis et al. 2015).

NozA and NcdA are putative cyclodipeptide synthases with homology to
Amir_4627, revealed via bioinformatics
The putative CDPSs NozA and NcdA, identified by bioinformatics
analyses are the most likely candidates for production of the cyclo(L-Trp-L-Trp)
DKP precursor in nocardioazine biosynthesis. Comparison of NozA and NcdA to
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other known CDPSs revealed both enzymes share all 8 residues conserved
among biochemically characterized CDPSs (Figure 5) (Moutiez et al. 2014). Of
the conserved residues, serine-36 is conserved among the active sites and is
necessary for recognition and covalent linkage of CDPSs to the aminoacyl group
from amioacyl-charged tRNA substrates (Moutiez et al. 2014).

Figure 5. Alignment of CDPSs NozA and NcdA encoded by Nocardiopsis sp. CMBM0232 with all biochemically characterized CDPSs. Secondary structures (grey) are
based upon features conserved for the structures of crystallized CDPSs AlbC, Rv2275,
and YvmC_lic. Residues conserved among all CDPSs are indicated with a *; these
include the serine active site (red). For crystallized CDPSs, basic residues from the α4
helix (blue) play roles in recognition of the first tRNA group. Residues in green and
yellow comprise the binding pocket of the first and second aminoacyl groups,
respectively, for indicated enzymes. Residues in pink refer to those specific to NozA,
NcdA and Amir_4627, the only substrate specific CDPSs the only ones known to
catalyze assembly of cyclo(L-Trp-L-Trp).
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Phylogenetic analysis of 11 previously characterized CDPSs based on
protein sequence homology organized the enzymes into three monophyletic
groups: one group incorporating aromatic amino acids, a second group
representative of the only CDPS from eukaryotic origin, and a third group
incorporating non-aromatic amino acids (Figure 6). NozA and NcdA were both
most closely related to CDPSs that incorporate aromatic substrates.

This

comparison also revealed that NozA and NcdA share 35 and 67% identity,
respectively, to Amir_4627 from Actinosynnema mirum, the only characterized
CDPS that incorporates two Trp residues (Figure 6). Amir_4627 is also the only
functionally characterized CDPS with specificity for one substrate. This
relatedness is suggestive that NcdA (67% ID to Amir_4627) may exhibit similar
activity to Amir_4627.

The sequence of NozA, more distantly related to

Amir_4627 (35% ID), is not as suggestive of biosynthesis of cyclo(L-Trp-L-Trp),
but is likely to incorporate aromatic amino acids based on its phylogenetic
relationship to other CDPSs catalyzing formation of aromatic DKPs (Figure 6).
Based on these bioinformatics predictions, characterization of both NozA and
NcdA was then undertaken to reveal the substrate specificity of both enzymes
and whether they may be involved in nocardioazine A biosynthesis by catalyzing
the production of the cyclo(L-Trp-L-Trp) precursor.
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Actinosynnema mirum Amir_4627 c(WW)
Nocardiopsis sp. CMB-M0232 NcdA c(??)
Mycobacterium tuberculosis Rv2275 c(YY)

a)#

Streptomyces noursei AlbC c(LF)
Nocardiopsis dassonvillei Ndas_1148 c(FY)
Nocardiopsis sp. CMB-M0232 NozA c(??)

b)#
Nematostella vectensis Nvec-CDPS2 c(WX)
Bacillus licheniformis YvmC-lic c(LL)
Bacillus licheniformis YvmC-sub c(LL)
Bacillus licheniformis YvmC-thu c(LL)
Staphylococcus haemolyticus pSHaeC06 c(LF)

c)#

Photorhabdus luminescens laumondii Plu0297 c(LL)
Corynebacterium jeikeium Jk0923 c(LL)

Figure 6. Phylogenetic tree of NcdA and NozA relative to all previously characterized
CDPSs. The CDPSs organized into three monophyletic groups: (a) CDPSs that
incorporate aromatic amino acids, (b) the single characterized CDPS from eukaryotic
origin, and (c) CDPSs that incorporate non-aromatic amino acids. The only previously
characterized CDPS that yielded cyclo(L-Trp-L-Trp), Amir_4627, is shown in purple.
Amir_4627 and NcdA (top blue box) share 67% identity. Amir_4627 and NozA (bottom
blue box) share 35% identity. Enzymes characterized in this current study are
highlighted in blue. The only previously characterized CDPS that yielded cyclo(L-Trp-LTrp) is shown in purple. The DKP product is shown with one-letter abbreviations for Lamino acids, e.g. cyclo(L-Trp-L-Trp) is listed as cWW. Most CDPSs are promiscuous;
only the product formed in greatest yield is indicated. The Nvec-CDPS2 product is
shown as cWX, since multiple amino acids were non-preferentially incorporated as the
second residue of the DKP. Protein accession numbers are listed in the appendix
(Appendix D).
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Recombinant expression of NozA and NcdA in E. coli
In order to produce NozA and NcdA in greater quantities than what is
provided by the native organism (Nocardiopsis sp.) and to facilitate enzyme
purification through tagging with an affinity label (e.g. hexahistidine), the
enzymes were recombinantly expressed in E. coli. Codon optimized nozA was
introduced into the pQE30 plasmid vector. Codon optimized ncdA was introduced
into plasmid vector pQE30 for in vivo characterization and pET30a(+) for in vitro
characterization. The constructs were then introduced into E. coli. Agarose gel
electrophoresis confirmed E. coli M15[pREP4] pQE30/nozA, E. coli M15[pREP4]
pQE30/ncdA, and E. coli BL21 (DE3) pET30a(+)/ncdA were successfully
constructed, showing both the vector and insert were present following
purification of plasmid DNA and restriction digest (Figure 7). This finding was
further confirmed by DNA sequencing, which revealed a perfect match between
the expected and experimental DNA sequence of gene inserts.
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a)

b)

Figure 7. Verification of assembly of constructs for E. coli expression of nozA and ncdA.
(a) Lane 1 contains GeneRuler 1 kb Plus DNA Ladder, lane 2 contains nozA (711 bp)
digested from pQE30 plasmid vector (3.4-Kb) and lane 3 contains ncdA (753 bp)
digested from pQE30 plasmid vector (3.4-Kb). (b) Lane 1 contains GeneRuler 1 kb Plus
Ladder and lane 2 contains ncdA (753 bp) digested from pET30a(+) (5.4-Kb).

E. coli pQE30/nozA and pQE30/ncdA were induced with IPTG to
upregulate expression of the genes encoding NozA and NcdA. The optical
density (OD600) measured before (~0.4) and after induction (~1.0) confirmed
uniform growth among all treatment (carrying nozA or ncdA) and control cultures
(carrying vector without biosynthetic genes). SDS-PAGE analysis of induced
control and both uninduced and induced treatment soluble lysates suggested
successful overexpression of both CDPSs as soluble proteins upon induction
with IPTG (Figure 8). With this confirmation of the expression of both NozA and
NcdA, the catalytic function of these enzymes was next probed.
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Figure 8. SDS-PAGE verifying the overexpression of NozA and NcdA in the soluble
lysates of recombinant E. coli upon induction with IPTG. Lane 1 contains BenchMark
Pre-Stained Protein Ladder (Life Technologies) and lane 2 contains soluble proteins
from the induced E. coli M15[pREP4] pQE30 vector control, containing no biosynthetic
genes. Lane 3 contains soluble proteins from the uninduced E. coli M15[pREP4] pQE30
vector control, containing no biosynthetic genes. Lanes 4-5 contain soluble proteins from
induced and uninduced M15[pREP4] pQE30/ncdA, respectively. Lanes 6-7 contain
soluble proteins from induced and uninduced M15[pREP4] pQE30/nozA, respectively.
Overexpression of proteins in observed in treatment lanes lanes 4 and 6 at the correct
NcdA and NozA respective molecular weights of 29- and 28-kDa, respectively.

Characterization of the functions of recombinantly expressed NozA and
NcdA in vivo
Metabolite profiles of supernatants from induced treatment and control
cultures were compared using HPLC to determine the presence of cyclo(L-Trp-LTrp) upon expression of NozA and NcdA in vivo. When compared to the empty
vector control, recombinant E. coli expressing NozA or NcdA produced a unique
HPLC UV signal (~23.7 min), matching the retention time of the signal created by
a synthetic cyclo(L-Trp-L-Trp) standard (Figure 9). High resolution LC/MS
analyses of the metabolites revealed almost identical molecular weights between
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the metabolites and synthetic standard, further supporting that both NozA and
NcdA catalyze the production of cyclo(L-Trp-L-Trp), the putative precursor in
nocardioazine biosythesis. The observed in vivo [M+Na]+ m/z for synthetic
cyclo(L-Trp-L-Trp) was 395.1472, for NozA cyclo(L-Trp-L-Trp) was 395.1470,
and for NcdA cyclo(L-Trp-L-Trp) was 395.1474.

mAU
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synthetic cyclo(L-Trp-L-Trp)
1500

pQE30/ncdA
1000

pQE30/nozA
500
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0

0

10

20

30

40

min

Figure 9. HPLC metabolite profiles for supernatants from IPTG-induced E. coli cultures
pQE30/nozA or pQE30/ncdA relative to control cultures featuring empty pQE30 vector.
A distinct signal at 23.7 minutes was observed in supernatants from treatment E. coli but
was absent from control E. coli carrying empty pQE30 vector. The retention time of the
metabolite matched that of synthetic cyclo(L-Trp-L-Trp) standard, supporting that both
NozA and NcdA are able to catalyze cyclo(L-Trp-L-Trp) assembly. Chromatograms show
absorbance at 280 nm.
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Probing the roles of conserved amino acid residues in catalysis by NozA
NozA, NcdA, and Amir_4627 are unique as the only CDPSs known to
catalyze formation of cyclo(L-Trp-L-Trp). Several residues conserved between
the protein sequences of NozA, NcdA and Amir_4627 were identified and
mutated in NozA using PCR-targeted site directed mutagenesis in order to
determine whether or not the conserved residues played a role in the enzyme’s
preference for tryptophan. Furthermore, a residue identified in AlbC proven to
play a critical role in the substrate preference of the enzyme was mutated in
NozA via PCR-targeted site directed mutagenesis to determine if changing that
residue would alter the substrate preference of NozA. The serine-36 residue
conserved among the functionally characterized CDPSs was also mutated in
NozA to determine whether that residue played a role in the active site of the
enzyme.
The optical density (OD600) measured before (~0.4) and after induction
with IPTG (~1.0) confirmed uniform growth among control (E. coli M15[pREP4]
carrying NozA with no site directed mutations) and treatment cultures (E. coli
M15[pREP4] carrying NozA with mutated residues). SDS-PAGE analysis of
treatment and control culture lysates verified uniform protein expression among
all cultures suggesting that nozA site directed mutations did not interfere with E.
coli growth (Figure 10).
Metabolite profiles of NozA site directed mutagens alongside controls
analyzed by HPLC revealed production of cyclo(L-Trp-L-Trp) was abolished upon
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mutation of the serine residue to an alanine in NozA’s active site (S36A). These
data imply that serine-36 plays an essential role in NozA catalysis and suggest
that NozA employs a catalytic mechanism analogous to that recently unveiled for
AlbC, (Moutiez et al. 2014) a CDPS 33% homologous to NozA. During the first
step of AlbC catalysis, the aminoacyl moiety from aa-tRNA is transferred onto the
serine active site. This aminoacyl group forms a peptide bond with an aminoacyl
moiety donated from a second aa-tRNA substrate, and the resulting dipeptidyl
intermediate then undergoes intramolecular peptide bond formation to close the
DKP ring and concomitantly release from the active site.
The other mutations did not alter the enzyme’s ability to catalyze the
production of cyclo(L-Trp-L-Trp), suggesting those conserved residues are not
critical in the enzyme’s substrate specificity (Figure 11). Additionally, production
of alternative cyclodipeptide metabolites due to the mutations made to NozA
were not observed.
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Figure 10. SDS-PAGE verifying uniform protein expression among E. coli M15[pREP4]
pQE30 carrying nozA with and without site directed mutations. Lane 1 contains
PageRuler Plus Prestained Protein Ladder, lane 2 contains pQE30 carrying no
biosynthetic genes, lane 3 contains pQE30/nozA (no mutations), lane 4 contains
pQE30/nozA-S36A, lane 5 contains pQE30/nozA-L131R, lane 6 contains pQE30/nozAS198L, lane 7 contains pQE30/nozA-N114R, lane 8 contains pQE30/nozA-N114A and
lane 9 contains pQE30/nozA-V111R+N114A. The optical density (OD600) following
fermentation with IPTG was ~1.0 for each culture, suggesting that the nozA site directed
mutations did not interfere with E. coli growth.
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Figure 11. HPLC metabolite profiles for E. coli M15[pREP4] producing NozA site
directed mutagens. A distinct signal at 23.7 minutes, indicating cyclo(L-Trp-L-Trp)
production, was observed in the supernatants from all treatments and controls except
the empty vector control carrying no biosynthetic genes and the S36A mutant, where the
serine active site residue was replaced with alanine. This confirmed the critical role of
the serine-36 residue for the catalytic function of NozA. Chromatograms show
absorbance at 280 nm.
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Characterization of the function and substrate preferences of purified
recombinant NozA and NcdA in vitro
By exploiting the hexahistidine tags incorporated into NozA and NcdA by
the expression plasmids, the purification of both enzymes began with standard
Ni-affinity chromatography (Figure 12, a-b). Subsequent purification by anion
exchange FPLC resulted in >90% pure NozA and NcdA for in vitro analysis of
enzyme functions and substrate preferences (Figure 12, c-d).
Previously characterized CDPSs were found to use aminoacyl-tRNAs as
substrates for the catalysis of 2,5-DKP biosynthesis (Moutiez et al. 2014). LC/MS
analysis following incubation of NozA and NcdA with tryptophanyl-tRNA in vitro,
revealed production of cyclo(L-Trp-L-Trp). Eliminating any one component of the
assay mixture (e.g. enzyme (NozA or NcdA), tryptophan, tRNA or aminoacyltRNA synthetase mix) resulted in no production of cyclo(L-Trp-L-Trp) (Figure 13
a). These results confirmed that NozA and NcdA, like other characterized
CDPSs, use aminoacyl-tRNA’s as their substrates to catalyze the production of
cyclo(L-Trp-L-Trp). Both NozA and NcdA are most closely related to CDPSs that
incorporate aromatic aminoacyl-tRNAs (Figure 6). In order to elucidate the
substrate specificity of NozA and NcdA, both enzymes were incubated with
tRNAs charged with alternative aromatic amino acids, L-tyrosine and Lphenylalanine. LC/MS analysis revealed that NozA and NcdA were not able to
catalyze the biosynthesis of alternative 2,5-DKPs using these aromatic
aminoacyl-tRNA substrates, revealing the substrate specificity of both enzymes
for L-tryptophan charged tRNA (Figure 13 a).
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a)

b)

c)

d)

Figure 12. SDS-PAGE analysis of NozA and NcdA purification via Ni-column and FPLC.
(a) NozA Ni-column eluents. Lane 1 contains PageRuler Unstained Protein Ladder
(Thermo Scientific), lane 2 contains total proteins, lane 3 contains total soluble proteins,
lane 4 contains the flow through fraction (containing 5 mM imidazole), lane 5 contains 10
mM imidazole eluent, lane 6 contains 50 mM imidazole eluent, lane 7 contains 200 mM
imidazole eluent and lane 8 contains 500 mM imidazole eluent. NozA (~28 kDa) was
eluted in the 200 mM imidazole fraction. (b) NcdA Ni-column eluents. Lane 1 contains
PageRuler Prestained Protein Ladder (Thermo Scientific), lane 2 contains the flow
through fraction (containing 5 mM imidazole), lane 3 contains 10 mM imidazole eluent,
lane 4 contains 50 mM imidazole eluent, lanes 5-6 contain sequential 100 mM imidazole
eluent, lanes 7-8 contain sequential 200 mM imidazole eluent and lane 9 contains 500
mM imidazole eluent. NcdA (~29 kDa) was eluted in both 200 mM imidazole fractions.
(c-d) FPLC fractions containing >90% pure NozA and NcdA. (c) Lane 1 contains
PageRuler Prestained Protein Ladder (Thermo Scientific) and lanes 2-5 contain purified
NozA (~28 kDa). (d) Lane 1 contains PageRuler Unstained Protein Ladder (Thermo
Scientific) and lanes 2-5 contain purified NcdA (~29 kDa). These >90% pure fractions
were pooled for in vitro analyses of enzyme functions.
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Figure 13. In vitro characterization of NozA and NcdA encoded by the Nocardiopsis sp.
CMB-M0232 genome. (a) LC/MS revealed that incubation of purified recombinant NozA
and NcdA with tryptophanyl-tRNA substrates yielded cyclo(L-Trp-L-Trp) in vitro.
Incubation with alternative aromatic amino acids yielded no alternative 2,5-DKPs (data
not shown), revealing substrate specificity of both enzymes for tryptophan-charged
tRNA. Plot shows LC/MS selected ion recording for cyclo(L-Trp-L-Trp) and for cyclo-3methyl-L-Trp-N1’-methyl-L-Trp DKP internal standard (I.S.). (b) These data support the
overall reaction catalyzed by both NozA and NcdA is to employ tryptophanyl-tRNA
substrates to yield cyclo(L-Trp-L-Trp) product.
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These experiments confirmed that NozA and NcdA from Nocardiopsis sp.
CMB-M0232 catalyze the production of cyclo(L-Trp-L-Trp) both in vivo and in
vitro. These results suggest both enzymes are involved in the biosynthesis of
nocardioazine A by producing the 2,5-DKP precursor in the biosynthetic pathway,
cyclo(L-Trp-L-Trp). These findings make NozA and NcdA two of only three
characterized CDPSs from prokaryotic origin to use tryptophanyl-tRNA as a
substrate and two of only three characterized CDPSs from any origin to exhibit
specificity for a single substrate. Fidelity is uncommon amongst characterized
CDPSs, making NozA and NcdA important CDPS family additions.
Characteristic to CDPS-containing biosynthetic pathways are DKPtailoring enzymes capable of modifying the CDPS-assembled substrates to
produce alternative natural products (Gondry et al. 2009, Sauguet et al. 2011,
Seguin et al 2011, Belin et al. 2012, Giessen and Marahiel, 2012, Giessen et al.
2013). Chapter three aims to identify putative cyclo(L-Trp-L-Trp) modifying
enzymes in the noz gene cluster to determine their roles in the modification of
cyclo(L-Trp-L-Trp) to produce nocardioazines A-B.
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Chapter III
Evaluation of tailoring enzymes with hypothesized roles in
nocardioazine A biosynthesis
Introduction
In prokaryotic organisms, genes involved in secondary metabolic
pathways are typically organized in operon-like structures within the genome,
spanning up to 100 kilobases or more (Lane and Moore, 2012). This organization
in prokaryotes greatly facilitates location of entire biosynthetic pathways
compared to eukaryotic organisms, where genes involved in a biosynthetic
pathway are often dispersed among the entire genome. Once a prokaryotic
biosynthetic gene cluster is located, modern molecular techniques allow probing
of individual players in the pathway to elucidate their enzymatic functions and
engineer synthesis of alternative metabolites.
In the case of peptide derived natural products, two biological strategies
exist for generating structural diversity: (1) changing the peptide backbone itself
or (2) modifying the scaffold with various tailoring enzymes (Giessen and
Marahiel, 2012). The majority of functionally characterized CDPSs exhibit
promiscuity in their aa-tRNA substrate specificity and are able to incorporate
multiple amino acids to generate several different 2,5-DKP backbones. NozA and
NcdA are two of only three CDPSs that exhibit substrate specificity, solely
catalyzing the production of cyclo(L-Trp-L-Trp) assembly. We focused on gaining
insight into the function of cytochrome P450 enzymes encoded within the same
operon as nozA. These enzymes were hypothesized to play roles in the late
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stages of biosynthesis of the nocardioazines (Figure 14), which share the
cyclo(Trp-Trp) backbone provided by the Nocardiopsis sp. CDPSs (Chapter 2).

Figure 14. Nocardioazine biosynthesis overview. (a) Schematic of proposed
intermediates in nocardioazine assembly, as established by comparison of synthetic
standards to metabolites from Nocardiopsis sp. (Alqahtani et al. 2015). In this thesis,
gene elimination mutations and feeding studies were employed in an effort to evaluate
the functions of NozD and NozE in the late stages of nocardioazine assembly. (b)
Overview of genes with predicted roles in nocardioazine assembly.

All CDPS-encoding biosynthetic pathways contain at least a single gene
encoding a DKP-modifying enzyme positioned upstream or downstream from the
CDPS gene, indicating that the DKPs generated are ultimately modified further to
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yield diverse chemical structures (Belin et al. 2012, Giessen and Marahiel, 2014).
This organization generates a mechanism for biosynthesis of standard cyclic
peptide scaffolds that can be modified by a variety of enzymes, incorporating
functional groups that result in unique biologically activities. Exploiting this
molecular method provides endless opportunities to synthesize new natural
products and therefore, new candidates for pharmaceutical drugs.
There are several enzymes characteristic to CDPS-containing pathways
that can be organized into three groups: modifying enzymes, regulators and
transporters (Giessen and Marahiel, 2014). Common classes of modifying
enzymes are hydrolases, methyltransferases, and acyl-CoA transferases. Among
all, the most common class of tailoring enzymes are the oxidases, with a
relatively high majority homologous to cytochrome P450s, enzymes that catalyze
a wide variety of oxidation reactions, including oxygenation reactions on a variety
of substrates by adding hydroxy and epoxide groups (Giessen and Marahiel,
2014). Common regulatory enzymes associated with CDPS-containing gene
clusters are transcription factors. Transcription factors trigger the expression of
genes in the biosynthetic pathways in response to environmental cues such as
oxidative stress, toxins and antibiotics. Membrane transporters are also common
among CDPS-containing gene clusters, generally responsible for exporting the
products of biosynthesis from the cell. Based on these three enzyme groups, it is
suggested that environmental cues trigger synthesis of CDPs, which are then
transported to the periplasm or extracellularly (Belin et al. 2012 & Giessen and
Marahiel, 2014).
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NozD and NozE, two cytochrome P450 homologs located directly
downstream from nozA (Figure 14 & 16; Table 1), were predicted via
bioinformatics analyses to modify the unique C3’-prenyl group of nocardioazine B
to form the epoxide ring characteristic to nocardioazine A and is critical to its
anticancer activity. In this chapter we aim to elucidate the roles of NozD and
NozE in nocardioazine A biosynthesis by expressing the genes in heterologous
Streptomyces hosts optimized for the expression of biosynthetic pathways from
actinomycetes. Constructs engineered to express the gene cluster containing
nozA, nozD and nozE (Gust et al. 2004, Smanski et al. 2012) as well as three
additional constructs featuring gene elimination mutations in the gene cluster
were engineered for expression in Streptomyces. To probe the functions of the
three genes from contig 557 (nozA, nozD and nozE) the heterologous
Streptomyces were exposed to nocardioazine B via in vivo and in vitro methods
and metabolite profiles were screened via HPLC to detect accumulation of
nocardiazine A.

Methods
Isolation of nocardioazines A-B from wild type Nocardiopsis sp. CMBM0232
M1 liquid media (20 mL) (10 g/L potato starch, 4 g/L yeast, 2 g/L peptone,
1 g/L CaCO3, 40 mg/L Fe2(SO4)5H2O, 100 mg/L KBr, pH 7) was inoculated with
wild type Nocardiopsis sp. CMB-M0232 from a -80 °C freezer stock and
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incubated for 6 days and 200 rpm at 30 °C. Following incubation, 5 x 1 L of M1
liquid media in Fernbach flasks were inoculated with 1 mL each of the 6-day
starter culture and incubated at 30 °C and 200 rpm for seven days. Following
incubation, the 5 L culture was filtered over Celite 545 (Fisher) and extracted with
an equal volume of ethyl acetate. The ethyl acetate was removed from the
aqueous extracts using a vacuum controlled rotavapor (BUCHI) and the
remaining traces of liquid were dried using a SpeedVac concentrator (Savant
ISS1100, Thermo Scientific) overnight.
Nocardiopsis sp. crude extracts (~600 mg from 5 L culture) were
subjected to sequential trituration with water, n-hexane, dichloromethane
(CH2Cl2), and methanol (MeOH) to begin to separate the nocardioazines from
other compounds. Specifically, the crude extracts were solubilized in 5 mL of
Milli-Q water and centrifuged (5,000 rpm for 10 minutes).

The supernatant,

consisting of water with soluble polar compounds, was discarded. The remaining
pellet composed of insoluble, nonpolar compounds was dried using a SpeedVac
concentrator (Savant ISS1100) and resolublized in n-hexane (50 mL).

The

suspension was centrifuged and the supernatant was transferred to a scintillation
vial, dried using a vacuum controlled rotavapor (BUCHI), and set aside for
LC/MS analysis. The remaining pellet from the hexane suspension was then
resolublized in CH2Cl2 (50 mL) and handled identically to the hexane suspension.
This was again repeated using MeOH (50 mL). Dried n-hexane, CH2Cl2 and
MeOH extracts were resolubilized in MeOH to a final concentration of 10 mg/mL
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and subjected to LC/MS analysis to determine which fraction contained the
majority of nocardioazine A-B.
LC/MS determined that the n-hexane fraction contained the highest
concentrations of nocardioazines A-B.

An aliquot (500 µL) of the n-hexane

extract (10 mg/mL) was subjected to HPLC using an Aligent 1100 HPLC system
with a ZORBAX SB-C18 column (9.4 x 250 mm, particle size: 5 µm, pore size of
110 Å). A flow rate of 3.5 mL/min was used, with solvent A consisting of MilliQ
water, solvent C consisting of acetonitrile and a linear gradient of 10 to 100%
solvent C over 25 minutes following an 5 minute hold at 10% solvent C. Fractions
were collected coming off the column in two-minute increments, concentrated
and analyzed by LC/MS to identify which peaks in the spectra (280 nm)
correspond to nocardioazine A-B. The respective peaks were collected from the
remainder of the hexane extracts, dried using a SpeedVac concentrator (Savant
ISS1100) and solubilized in 100% chloroform-d (Alfa Aesar) to verify their
chemical structures by nuclear magnetic resonance (NMR).

Generation of heterologous constructs for expression of contig 557 in
Streptomyces coelicolor M1152 and Streptomyces lividans TK24
The SuperCos 1 cosmid clone carrying contig 557, featuring the noz gene
cluster (Figure 14 & 16, Table 1), was modified for introduction and expression in
Streptomyces hosts following protocols described by Smanski et al. (2012).
Specifically, SuperCos-1 (Agilent) carrying contig 557 from a cosmid clone library
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generated as described by Bis et al. (2015) was modified by λ-RED E. coli
recombination to introduce oriT, an origin of conjugal transfer, Streptomyces
θC31 integrase to facilitate integration into the attB site of Streptomyces’
chromosome, and aac(3)IV, an apramycin resistance gene for selection.
A 270 bp fragment of the 3’ end of the bla gene from SuperCos 1 was
amplified using methods and primers described by Smanski et al. and cloned into
the XbaI/BamHI sites in the Streptomyces-integrating vector, pSET152 (Bierman
et al. 1992) which encodes aac(3)IV, oriT and θC31 integrase. The
pSET152/3’bla construct was then linearized at BamHI and EcoRI restriction
sites and introduced into λ-RED recombination proficient E. coli BW25113/pIJ790
carrying SuperCos/contig 557 to undergo homologous recombination between
the homologous pUC and 3’ -bla sites of the SuperCos backbone. PCR and DNA
sequencing were used to confirm the presence of aac(3)IV, oriT and θC31
integrase in SuperCos/contig 557A, the product of this recombination event
(Appendix C, SuperpSET_F/R). E. coli ET12567/pUZ8002 was transformed with
SuperCos/contig 557A to facilitate conjugation into Streptomyces coelicolor
M1152 and Streptomyces lividans TK24 using standard methods described by
Gust et al. (2004). PCR confirmed successful integration of contig 557 genes into
the S. coelicolor M1152 and S. lividans TK24 chromosome (Appendix C,
NozACtg557_F/R).
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In vivo and in vitro characterization of NozD and NozE heterologously
expressed in Streptomyces
NozD and NozE, cytochrome P450 homologs (Table 1) were predicted via
bioinformatics analyses as the most likely candidates for the modifications made
to nocardioazine B to produce nocardioazine A, which requires cyclizing of the
C3’-prenyl group on nocardioazine B to form the epoxide ring on nocardioazine A
(Figure 14). To determine the role of NozD and NozE in this catalytic reaction, in
vivo and in vitro experiments were designed using heterologous Streptomyces
carrying the entire contig 557 including NozA, NozD and NozE.
For the in vivo approach, S. coelicolor M1152 and S. lividans TK24
heterologously expressing the contig 557 gene cluster (including NozA, NozD
and NozE) were cultured in media supplemented with nocardioazine B, extracted
and analyzed for the presence of nocardioazine A. Specifically, 100 µL of 3-day
starter cultures of heterologous S. coelicolor M1152 and S. lividans TK24 carry
contig 557 were inoculated into 25 mL of M1 media supplemented with 50 µg/mL
apramycin in 250 mL Erlenmeyer flasks. Wild type S. coelicolor M1152 and S.
lividans TK24 carrying no biosynthetic genes were cultured alongside as
controls, lacking apramycin. Two 25 mL cultures of each treatment and control
strain were prepared and supplemented as follows prior to fermentation. One
culture of each wild type strain and heterologous strain was supplemented with
250 µg nocardioazine B that was solubilized in dimethyl sulfoxide (DMSO). The
second set of cultures was supplemented with equal volumes of DMSO to serve
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as controls. The treatment and control cultures were incubated at 30 °C and 200
rpm for 6 days.
Following incubation, the cultures were extracted with 25 mL of EtOAc and
the chemical extracts were concentrated using a vacuum controlled rotavapor
(BUCHI) followed by a SpeedVac concentrator (Savant ISS1100, Thermo
Scientific) overnight. The extracts were resolubilized in 250 uL MeOH for analysis
by HPLC to determine whether NozD and NozE were able to convert
nocardioazine B to nocardioazine A. The HPLC method mentioned previously
was run with known concentrations of cyclo(L-Trp-L-Trp) (0.2 mg/mL),
nocardioazine B (25 µM) and nocardioazine A (25 µM) to serve as positive
controls.
The in vitro approach offered an alternative that exposed nocardioazine B
to cell lysates containing NozD and NozE rather than requiring nocardioazine B
enter the cell as in the in vivo methods. Specifically, 200 µL of 3-day starter
cultures of heterologous S. lividans TK24 carrying contig 557 (NozA, NozD and
NozE) were inoculated into 50 mL of M1 media supplemented with 50 µg/mL
apramycin in 250 mL Erlenmeyer flasks. Wild type S. lividans TK24 was cultured
alongside as a control, lacking apramycin.

Following 3 days and 6 days of

incubation at 30 °C and 200 rpm, 25 mL of each culture (wild type control and
treatment carrying contig 557) were transferred to 50 mL falcon tubes. The cells
were harvested by centrifugation (6,000 rpm, 4°C) and were resuspended in 3
mL lysis buffer (100 mM Tris HCl, 150 mM NaCl, 5% glycerol, 2 mM DTT, pH 8)
with lysozyme (3.75 mg). The cell suspensions were sonicated at 60% amplitude
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for 3 minutes (1 s pulse:10 s rest). Cell debris was removed by centrifugation
(12,000 rpm, 4 °C) and the soluble lysates were filtered through a 0.45 µM
cellulose acetate membrane (Corning). In 1.5 mL microtubes, 100 µL of cell
lysates were combined with 20 µL of DMSO-solubilized nocardioazine (100 µg).
To serve as controls, duplicate assays were set up that combined 100 µL of cell
lysates with 20 µL of DMSO (no addition of nocardioazine B). The assays were
incubated ~16 hours at 30 °C. Following incubation, the assays were extracted
with 1 mL EtOAc and the chemical extracts were dried using a vacuum controlled
rotavapor (BUCHI) followed by a SpeedVac concentrator (Savant ISS1100,
Thermo Scientific) overnight. The extracts were resolubilized in 100 uL MeOH for
analysis by HPLC, described previously, to determine whether NozD and NozE
converted nocardioazine B to nocardioazine A.

Generation of PCR-targeted gene replacements in the contig 557 gene
cluster for heterologous expression in Streptomyces coelicolor M1152 and
Streptomyces lividans TK24
Additional constructs were created with PCR-targeted gene deletions to
further probe the enzymatic functions of NozA and the two cytochrome P450s
encoded downstream from nozA, referred to a NozD and NozE. Three constructs
were designed, each with one of the three abovementioned genes deleted in a
manner that would not interfere with expression of the other genes following
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procedures described by Smanski et al. (2012) and Gust et al. (2004) (Figure
15).
Specifically, gene disruption was carried out via PCR to replace each
targeted biosynthetic gene with an apramycin resistance cassette flanked with
FLP recognition targets (FRTs) (Figure 15 a). The FRTs were engineered into
the cassettes for FLP recombinase-induced excision of the apramycin resistance
gene to yield an in-frame scar in place of the gene. First, PCR was conducted to
amplify the FLP-flanked apramycin resistance gene by using primers with regions
homologous to the region immediately up- and downstream from the biosynthetic
gene targeted for replacement (Figure 15 a). The PCRs contained 36 µL of
molecular biology grade water, 0.5 µL of each forward and reverse primer
(NozX::scarKO_F/R, Appendix C) (0.5 µM final concentration), 5 µL of 10X
Expand High Fidelity Buffer with MgCl2 (Roche), 0.5 µL of High Fidelity dNTPs
(10 mM final concentration of each dNTP), 2.5 µL of DMSO, 0.5 µL (~50 ng) of
template DNA (AprR cassette from pIJ773 vector) and 1 µL of Expand High
Fidelity Enzyme Mix (Roche). The PCR reactions ran for an initial denaturation of
94 °C for 2 min, 10 cycles of 94 °C for 45 s, 50 °C for 45 s, 72 °C for 90 s, 15
cycles of 94 °C for 45 s, 55 °C for 45 s, 72 °C for 90 s and a final extension of 72
°C for 5 min. The PCR products were verified for size by agarose gel
electrophoresis and the remaining PCR product was purified using a QIAquick
PCR Purification Kit.
Following

amplification

of

the

apramycin

resistance

cassette,

SuperCos/contig 557 was introduced into E. coli BW25113/pIJ790 via
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electroporation (Figure 15 b). Next, the PCR-amplified apramycin resistance
cassette was introduced into E. coli BW25113/pIJ790/SuperCos/contig 557
(Figure 15 b). In three separate constructs, one of each of the desired genes
(nozA, nozD or nozE) was replaced with the FRT-flanked apramycin resistance
cassette, aac(3)IV, via λ-RED recombination to generate SuperCos/nozA::AprR,
SuperCos/nozD::AprR and SuperCos/nozE::AprR constructs (Figure 15 c). PCR
confirmed recombination between the SuperCos/contig 557 cosmids and the
AprR cassette.
Prior to conjugation with Streptomyces, the SuperCos/contig 557
constructs carrying apramycin disruption cassettes in place of nozA, nozD, or
nozE required further modification. This modification required exploiting FLP
recombinase to replace the disruption cassette with an 81 bp scar to create nonpolar, in-frame deletions (nozA::scar, nozD::scar, nozE::scar). SuperCos carrying
the apramycin disruption cassettes were introduced into E. coli DH5α/BT340 (E.
coli Genetic Stock Center: Strain# 7629) via standard electroporation (Figure 15
d). Incubation at 42 °C induced expression of the FLP-recombination plasmid,
BT340, to express FLP-recombinase, which recognizes the FRT regions,
resulting in excision of the apramycin resistance cassette. This leaves behind an
81 bp “scar” in the correct reading frame (Figure 15 e). PCR confirmed the
presence

of

the

81

bp

“scars”

in

each

construct

(Appendix

C,

NozX_KOCon_F/R).
Following protocols mentioned in the previous section, these three
SuperCos cosmids now carrying the contig 557 with an 81 bp “scar” in place of
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NozA, NozD or NozE were again introduced into λ-RED recombination proficient
E. coli BW25113/pIJ790 carrying the previously constructed pSET152/3’bla
linearized plasmid DNA (Smanski et al. 2012). Homologous recombination
between the pUC origin of replication and 3’ -bla sites introduced oriT,
Streptomyces θC31 integrase, and aac(3)IV into SuperCos to facilitate
conjugation (Figure 15 f). PCR and DNA sequencing were used to confirm the
presence of aac(3)IV, oriT and θC31 integrase in the products of the
recombination event (Appendix C, SuperpSET_F/R).
Each of the SuperCos/noz::scar constructs (nozA::scar, nozD::scar,
nozE::scar) were introduced into E. coli ET12567/pUZ8002 to facilitate
conjugation into S. coelicolor M1152 and S. lividans TK24 using standard
methods described by Gust et al. (2004) (Figure 16 g-h). PCR amplification
confirmed successful integration of the nozA::scar, nozD::scar and nozE::scar
constructs into Streptomyces chromosome (Appendix C, NozX_KOCon_F/R).
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Figure 15. Methods for generating PCR-targeted gene deletions in the noz gene cluster
and introducing the constructs into heterologous Streptomyces via conjugation. (a) An
apramycin resistance cassette from pIJ773 was PCR amplified using primers that
introduced homologous regions of the gene to be deleted both upstream and
downstream from the apramycin resistance cassette. (b) SuperCos1-contig 557 from the
cosmid clone library and the PCR amplified apramycin resistance cassette were both
introduced into E. coli BW25113/pIJ790 to undergo homologous recombination. (c)
Homologous recombination replaced the targeted gene in contig 557 with the apramycin
resistance cassette. (d) SuperCos/contig 557/noz::AprR was introduced into E. coli
DH5α/BT340. (e) FLP-recombinase was expressed by the BT340 plasmid, which
recognized FRT sequences flanking the apramycin resistance cassette and excised the
cassette, leaving behind an 81-bp, in frame ‘scar’. (f) SuperCos/contig 557/noz::scar was
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introduced into E. coli BW25113/pIJ790 and underwent homologous recombination with
pSET152/bla to introduce elements into the plasmid DNA necessary for conjugation with
Streptomyces chromosome. (g) SuperCos/contig 557/noz::scar underwent conjugation
with Streptomyces to integrate the SuperCos plasmid into Streptomyces via homologous
recombination. (h) SuperCos/contig 557/noz::scar was introduced into Streptomyces
chromosome.

Comparison of metabolite profiles between heterologous S. coelicolor
M1152 and S. lividans TK24 carrying contig 557 or contig 557/nozA::scar,
nozD::scar or nozE::scar
Metabolite profiles were compared between Streptomyces featuring
heterologous noz cluster expression constructs (contig 557, nozA::scar,
nozD::scar and nozE::scar) to screen for the production of alternative metabolites
as a result of the PCR-targeted gene replacements. Specifically, one hundred
microliters of 3-day starter cultures of heterologous S. coelicolor M1152 and S.
lividans TK24 constructs (contig 557, nozA::scar, nozD::scar, nozE::scar) were
inoculated into 10 mL of M1 media (lacking Instant Ocean) supplemented with 50
µg/mL apramycin in 50 mL falcon tubes. Wild type S. coelicolor M1152 and S.
lividans TK24 were cultured alongside as controls lacking the addition of
apramycin. The treatment and control cultures were run in duplicates and
incubated at 30 °C and 200 rpm for 5 days. Following incubation, the cultures
were extracted with 10 mL EtOAc. The chemical extracts were dried using a
vacuum controlled rotavapor (BUCHI) and the remaining extracts were dried
using a SpeedVac concentrator (Savant ISS1100, Thermo Scientific) overnight.
The extracts were resolubilized in 150 µL MeOH for analysis by HPLC, described
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previously. Chemical profiles produced were compared using ChemStation
(Agilent).

Results and Discussion
Bioinformatics analyses predicted biosynthetic pathways from
Nocardiopsis sp.
FGENESB (Softberry) was used to predict putative genes and their
corresponding protein sequences upstream and downstream from nozA and
ncdA, CDPSs responsible for catalyzing cyclo(L-Trp-L-Trp) assembly. The CDPS
enzymes were found to reside in two different regions of Nocardiopsis sp.
genome, resulting in two CDPS-containing biosynthetic gene clusters, referred to
as contig 557 and contig 96 (Table 1, Figure 16 a-b). The contig 557 gene cluster
spans approximately 15 Kb and contains a CDPS homolog (nozA) along with
several other putative DKP tailoring enzymes. Two tailoring enzymes of interest
within the contig 557 gene cluster were identified as cytochrome P450 homologs
and named NozD and NozE. The genes encoding NozD and NozE are located
directly downstream from nozA and play hypothesized roles in the cyclization of
the C3’-normal prenyl group of nocardioazine B to yield the group observed in
nocardioazine A (Table 1, Figure 16 a). Additional bioinformatics analyses of
Nocardiopsis sp. CMB-M0232 genome revealed another gene cluster, contig
119, with hypothesized roles in nocardioazine biosynthesis (Table 1, Figure 16
c). A putative prenyltransferase, NozC, is hypothesized to catalyze the C3’-
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normal prenylation of the DKP core first seen in nocardioazine B. In this same
gene cluster and directly upstream from NozC is NozB, a putative
methyltransferase with hypothesized roles in C- and N-methylations of the DKP
scaffold also first seen in nocardioazine B (Figure 14).

	
   59	
  

Table 1. Predicted functions and homologs of putative proteins encoded by the
hypothesized nocardioazine biosynthetic gene clusters: contig 557, contig 96 and contig
119. # aa = number of amino acid residues; ID = % identity; Sim = % Similarity.
contig 557
# aa
genes (bp)
1512-2777

421

2842-4050

402

4093-4155

20

4235-4939

234

5023-6219
6312-7373
7451-9994

398
353
847

10221-10550 109
10810-11733 307
11721-12809 362
12806-13675 289
13947-14780 277
14773-15183 136
15254-15904 216

contig 96
# aa
genes (bp)
1-379
431-1063
1527-3068
3083-3811
3897-4760
4924-5283
5502-6452
6846-7481

126
210
513
242
287
119
316
211

7689-9269

526

9435-9824
9947-10945
10970-11806
11949-12185
12310-12423
12967-13338

129
332
278
78
37
123

contig 119
# aa
genes (bp)
105-1118
1223-2152
2501-3805
3916-4554
4551-5627
5668-8013

337
309
434
212
358
781

NCBI accession
number of homolog

ID / Sim
(%)

WP_037674793

56/69

AEF16056

58/72

KFA31228

73/90

WP_033352817

42/53

WP_045298286
WP_045298286
ELQ79671

40/54
40/54
58/69

WP_020270970

75/87

WP_044572329

80/89

WP_046471802

73/82

WP_017566834
WP_046471807

76/88
71/78

WP_017544945

76/84

ERT00338

36/52

NCBI accession
number of homolog

ID / Sim
(%)

WP_033301593
WP_033301600
WP_042418882
WP_035283888
WP_026126175
WP_017620737
WP_046725140
WP_011211565

72/83
36/49
74/82
70/80
63/71
69/84
38/51
58/74

WP_041588039

40/57

WP_033381084
WP_015051569
WP_037956543
WP_031172074
AGL28386
WP_019609329

78/85
41/55
55/72
57/70
52/58
57/62

BLASTP annotation

NCBI accession
number of homolog

ID / Sim
(%)

hypothetical protein
3-ketoacyl-ACP reductase
glycosyl transferase family 1
methyltransferase
prenyltransferase
hypothetical protein

WP_017620974
WP_026126235
WP_017620972
WP_046468151
WP_033301783
WP_040270987

73/82
77/84
85/92
86/92
79/84
69/81

BLASTP annotation
pyridoxas-5'-phosphate-dependent
protein subunit beta
major facilitator superfamily
transporter
beta-N-acetylglucosaminidase
tRNA-dependent cyclodipeptide
synthase
cytochrome P450
cytochrome P450
adenylocsuccinate synthetase
4-carboxymuconolactone
decarboxylase
XRE family transcriptional regulator
ABC transporter ATP-binding
protein
molybdate ABC transporter
molybdate-binding protein
MerR family transcriptional
regulator
hypothetical protein

BLASTP annotation
cell division protein
hypothetical protein
AMP-dependent synthetase
CDPS
cell wall hydrolase
hypothetical protein
erythromycin esterase
transcriptional regulator
peptide ABC transporter substratebinding protein
extradiol dioxygenase
nickel ABC transporter permease
serine protease
multidrug transporter
polyketide synthase PKS1
beta-galactosidase
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a)

b)

c)

~2 Kb
Predicted Protein Functions:
Cyclodipeptide synthase

Antibiotic resistance or transport

Cytochrome P450

Transcription regulator

Methyltransferase

Prenyltransferase

Hypothetical or other

Figure 16. Bioinformatics-predicted Nocardiopsis sp. gene clusters with hypothesized
roles in cyclo(L-Trp-L-Trp) and nocardioazine A-B biosynthesis. Cluster a) represents
contig 557 which spans ~15 Kb, b) represents contig 96 which spans ~15 Kb and c)
represents contig 119, spanning ~8 Kb. Arrows indicate the predicted direction of gene
transcription. Chapter 2 established the function of the cyclodipeptide synthases (red) in
production of cyclo(L-Trp-L-Trp).

Most CDPS-containing natural product biosynthetic pathways carry genes
encoding oxidases and almost all contain a gene encoding a cytochrome P450.
But, contig 557 presents the only identified natural product biosynthetic pathway
thus far that encodes two cytochrome P450s directly downstream from a CDPS
gene, suggestive of unique tailoring capabilities from the contig 557 gene cluster.
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Isolation of nocardioazines A-B from wild type Nocardiopsis sp. CMBM0232
Nocardioazines A-B were isolated from wild type Nocardiopsis sp. CMBM0232 in order to ‘feed’ heterologous Streptomyces the putative precursors in
nocardioazine A biosynthesis and to provide a standard of the pathway end
product, nocardioazine A. Following EtAOc extraction of wild type Nocardiopsis
sp. CMB-M0232, the crude extracts were subjected to sequential trituration to
concentrate the nocardioazines in a single fraction. LC/MS identified the largest
quantities of nocardioazine A-B present in the n-hexane extracts, a result of their
relatively non-polar chemical structures. To determine which peaks from the nhexane fraction HPLC spectra were representative of nocardioazines A-B,
eluents were collected from the HPLC column in two-minute increments. LC/MS
identified that nocardioazine A eluted from the column between minutes 26 and
28 (Figure 17 a) and nocardioazine B eluted from the column between minutes
28 and 30 (Figure 17 b). LC/MS then confirmed the individual peaks within those
time frames that were representative of nocardioazine A-B. From 5 L of
Nocardiopsis sp. CMB-M0232 culture, ~3.0 mg of nocardioazine B (pale white
powder) was purified and ~1.5 mg of nocardioazine A (pale white powder) was
purified. NMR validated the chemical structure of the purified compounds,
confirming isolation of pure, nocardioazines B and nocardioazine A (Appendix EF).
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Figure 17. HPLC spectra of n-hexane extracts that contain (a) nocardioazine A and (b)
nocardioazine B. Peaks (a) and (b) were collected and their contents verified via NMR.
Chromatogram shows absorbance at 280 nm.

Generation of noz cluster constructs for heterologous expression in
Streptomyces
To facilitate conjugation with Streptomyces, the SuperCos cosmid from
the gDNA clone library carrying contig 557 (called SuperCos/557 and featuring
the noz cluster of genes including nozA, nozD and nozE) as well as the
SuperCos cosmids carrying contig 557 featuring PCR-targeted mutants
(nozA::scar, nozD::scar and nozE:: scar) underwent homologous recombination
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with a fragment of the pSET152 plasmid vector to introduce the following
elements into SuperCos: aac(3)IV, oriT and θC31 integrase. These components
are essential for the introduction and expression of genes carried by SuperCos
(i.e.

noz

genes)

in

Streptomyces

hosts.

PCR

confirmed

homologous

recombination between SuperCos constructs carrying mutated (noz::scars) and
unmutated contig 557 and the linearized pSET152 plasmid vector using two sets
of primers that were designed to amplify both ends of the region where this DNA
was introduced into SuperCos. The constructs confirmed to carry all three
elements were introduced into S. coelicolor M1152 and S. lividans TK24 (Figure
18) by conjugation.

Figure 18. Agarose gel verifying homologous recombination between SuperCos1
featuring Streptomyces gene expression elements from pSET152 plasmid vector. Lanes
2-5 contain the amplified region of the constructs spanning the pUC-AprR gene and were
expected to amplify a 1301 bp product. Lanes 6-9 contain the amplified region of the
constructs linking the bla from SuperCos with pSET152 and were expected to amplify a
700 bp product. Lane 1 contains GeneRuler 1 kb Plus DNA Ladder, lanes 2 and 6
contain SuperCos carrying contig 557, lanes 3 and 7 contain SuperCos carrying the
nozA::scar, lanes 4 and 8 contain SuperCos carrying the nozD::scar, and lanes 5 and 9
contain SuperCos carrying the nozE::scar.
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Following conjugation, candidate Streptomyces transformants were
screened via PCR to confirm the incorporation of contig 557 or the contig 557
featuring PCR-targeted mutants (nozA::scar, nozD::scar and nozE::scar) into
Streptomyces chromosome. The ~3 Kb region of the contig 557 gene cluster
carrying nozA, nozD and nozE was confirmed present in both S. coelicolor
M1152 and S. lividans TK24 transformants using PCR (Figure 19). The mutants
were also confirmed present in both strains of Streptomyces transformants
(Figure 20). The unmutated contig 557 gDNA served as a positive control to
identify successful gene replacement and allow comparison of metabolites
between treatments and controls. Colony PCRs of cultures featuring contig 557
revealed amplification of the gene of interest. Replacement of the gene with an
81 bp-scar resulted in the expected reduction of the PCR product size.

Figure 19. Agarose gel verifying integration of contig 557, containing nozA, nozD and
nozE, into S. coelicolor M1152 and S. lividans TK24. Lane 1 contains GeneRuler 1kb
Plus DNA Ladder and lanes 2-4 contain contig 557 integrated into S. coelicolor M1146
which was not used in this current thesis study due to failed conjugation of mutant contig
557 constructs with S. coelicolor M1146. Lanes 5-7 contain contig 557 integrated into S.
coelicolor M1152, lanes 8-9 contain contig 557 integrated into S. lividans TK24, and lane
10 contains the pSET152/contig 557 cosmid to serve as a PCR control. PCR amplified
an ~500 bp region of nozA to confirm the presence of the contig 557 gene cluster in
Streptomyces.
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a)

b)

c)
Figure 20. Agarose gels verifying integration of contig 557 gene elimination mutations
via PCR-targeted gene deletions into S. coelicolor M1152 and S. lividans TK24. (a-c)
Lane 1 contains GeneRuler 1kb Plus DNA Ladder, lanes 2-3 contain S. lividans TK24
and S. coelicolor M1152 carrying the contig 557/noz::scars, respectively, lanes 4-5
contain S. lividans TK24 and S. coelicolor M1152 carrying contig 557 (unmutated),
respectively, and lane 6 contains SuperCos-1 carrying contig 557 to serve as a PCR
control. Gel (a) contains Streptomyces carrying the contig557/nozA::scar constructs, gel
(b) contains Streptomyces carrying the contig557/nozD::scar constructs, and gel (c)
contains Streptomyces carrying the contig557/nozE::scar constructs. The reduction in
size observed in the gene deletion constructs indicates deletion of that gene compared
to the constructs carrying the entire gene cluster.
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In vivo characterization of functions of NozD and NozE exposed to
nocardioazine B to evaluate their roles in biosynthesis of nocardioazine A
Nocardioazine B, purified from wild type Nocardiopsis sp. CMB-M0232,
was fed to Streptomyces expressing contig 557 genes, including nozA, nozD and
nozE. HPLC was used to evaluate accumulation of nocardioazine A from these
cultures, since NozD and/or NozE were hypothesized to catalyze the
transformation of nocardioazine B to nocardioazine A. Metabolite profiles were
compared between control, wild type S. lividans TK24 and S. coelicolor M1152,
with treatments of these strains carrying the contig 557 gene cluster (including
nozA, nozD, and nozE) following fermentation supplemented with nocardioazine
B (Figure 21-22). HPLC spectra were compared to synthetic cyclo(L-Trp-L-Trp)
and pure nocardioazine A-B standards to determine the presence of these
metabolites. Cyclo(L-Trp-L-Trp) was present in all metabolite profiles from
Streptomyces carrying the contig 557 gene cluster, supporting that the gene
encoding NozA was translated in the correct reading frame and therefore,
suggesting NozD and NozE from the same operon were present in the cells as
well. Nocardioazine B was detected by HPLC in samples in which it was
supplemented, but nocardioazine A was not detected in the chemical profiles of
Streptomyces expressing NozD and NozE and provided nocardioazine B (Figure
21-22). It is unclear whether or not nocardioazine B was able to enter the cells to
interact with NozD and NozE, offering one possibility as to why there was no
detectable accumulation of nocardioazine A. Thus, an in vitro approach was

	
   67	
  

undertaken to circumvent the issue of nocardioazine B entering the cell and
instead allow for direct contact between nocardioazine B, NozD and NozE.
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Figure 21.
HPLC spectra comparing metabolite profiles from heterologous
Streptomyces lividans TK24 carrying contig 557 exposed to nocardioazine B and not
exposed to nocardioazine B, in vivo.
Synthetic cyclo(L-Trp-L-Trp) and purified
nocardioazines A-B serve as controls. Following fermentation of S. lividans TK24
carrying contig 557 in media supplemented with nocardioazine B, nocardioazine A was
not detected. Chromatograms show absorbance at 254 nm.
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Figure 22.
HPLC spectra comparing metabolite profiles from heterologous
Streptomyces coelicolor M152 carrying contig 557 exposed to nocardioazine B and not
exposed to nocardioazine B, in vivo.
Synthetic cyclo(L-Trp-L-Trp) and purified
nocardioazines A-B serve as controls. Following fermentation of S. coelicolor M1152
carrying contig 557 in media supplemented with nocardioazine B, nocardioazine A was
not detected. Chromatograms show absorbance at 254 nm.

In vitro characterization of functions of NozD and NozE when exposed to
nocardioazine B to evaluate their roles in biosynthesis of nocardioazine A
Following the in vivo results failing to show NozD- or NozE-catalyzed
conversion of nocardioazine B to A, an alternative in vitro approach was taken to
probe the enzymatic activity of NozD and NozE. In vitro assays combined cell
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lysates from control, wild type S. lividans TK24 and treatments of this strain
carrying the contig 557 genes (nozA, nozD and nozE) with pure nocardioazine B.
The metabolite profiles from the previous mentioned assays were compared to
the chemical profiles from control and treatment S. lividans TK24 lysates that
were incubation without the addition of nocardioazine B (Figure 23). This
approach did not require that nocardioazine B enters the cell to interact with
NozD and NozE, but instead provided direct contact between nocardioazine B
and the cell lysates containing the cytochrome P450s, NozD and NozE.
HPLC metabolite profiles were compared to the cyclo(L-Trp-L-Trp) and
nocardioazine A-B standards to detect the presence of these metabolites. As
expected, cyclo(L-Trp-L-Trp) was present in all metabolite profiles from
Streptomyces carrying the contig 557 gene cluster. Nocardioazine B was
detected in the samples in which it was supplemented but Nocardioazine A was
not detected in the chemical profiles where Streptomyces expressing NozD and
NozE were provided nocardioazine B in vitro. These data suggested that either
NozD and/or NozE were not adequately expressed, lacked essential cofactors for
activity when expressed in Streptomyces hosts, or catalyzed reaction(s) other
than the modifications of nocardioazine B to A. Thus, the possibility that these
enzymes carry out other modifications of cyclo(L-Trp-L-Trp), from NozA, was
next explored.
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Figure 23. HPLC spectra comparing metabolite profiles from in vitro treatment assays
that combined cell lysates from Streptomyces lividans TK24 carrying contig 557 with
nocardioazine B and control assays where lysates incubated without the addition of
nocardioazine B (blue). Treatments included cell lysates from 3-day (red) and 6-day
cultures of Streptomyces treatments incubated with nocardioazine B (green). Following
incubation of the lysates with nocardioazine B, nocardioazine A was not detected.
Furthermore, no alternative metabolites were detected in assays incubated with
nocardioazine B compared to the control that was incubated without the addition of
nocardioazine B. Chromatograms show absorbance at 210 nm.

Comparing chemical profiles of heterologous Streptomyces noz pathway
cultures carrying PCR-targeted gene mutants to evaluate the accumulation
of alternative DKP-derived natural products
Since the previous experiments failed to establish enzymatic functions of
NozD and NozE in conversion of nocardioazine B to A, we next explored the
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possibility that these enzymes directly modify cyclo(L-Trp-L-Trp). Metabolite
profiles from Streptomyces carrying individual PCR-targeted mutations from the
contig 557 cluster (nozA::scar, nozD::scar or nozE::scar) were compared to
Streptomyces carrying the entire contig 557 gene cluster to detect accumulation
of alternative metabolites accumulated upon deletion of any of the three genes
(Figure 24-25). Cyclo(L-Trp-L-Trp) was present in each metabolite profile from
heterologous Streptomyces except the nozA::scar mutant, where nozA was
deleted. This further linked nozA to the production of cyclo(L-Trp-L-Trp) and
corroborated the finding from chapter 2. The presence of cyclo(L-Trp-L-Trp) in
the other constructs suggested that the genes were being translated in the
correct reading frame and that polar effects did not result from gene deletions.
No metabolites were present in Streptomyces carrying contig 557 but
missing from those carrying the nozD::scar and nozE::scar gene mutants by
HPLC (Figure 24-25). Thus, the enzymatic functions of the cytochrome P450s,
NozD and NozE, are still yet to be confirmed. Similarities of the chromosomal
region surrounding nozA to other CDP-modifying biosynthetic pathways, still
suggest that contig 557 contains likely candidates for the tailoring of
nocardioazine B to form nocardioazine A.

Further studies utilizing purified

recombinant enzymes may allow establishment of the functions of NozD and
NozE by permitting careful control over enzyme concentrations, cofactors, and
other variables that strongly impact enzyme activity. This thesis study sets the
stage for such future studies.
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Figure 24. HPLC spectra comparing metabolite profiles between heterologous
Streptomyces lividans TK24 carrying the full 557 gene cluster (nozA, nozD and nozE)
and those carrying the PCR-targeted gene mutants (nozA::scar, nozD::scar and
nozE::scar). Synthetic cyclo(L-Trp-L-Trp) served as a control. Depletion of cyclo(L-TrpL-Trp) production in the nozA::scar mutant further confirmed the function of nozA in
cyclo(L-Trp-L-Trp) assembly. No metabolites differed between metabolite profiles from
S. lividans TK24 carrying contig 557 and those carrying contig 557 with PCR-targeted
gene deletions. Chromatograms show absorbance at 210 nm.
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Figure 25. HPLC spectra comparing metabolite profiles between heterologous
Streptomyces coelicolor M1152 carrying the full 557 gene cluster (nozA, nozD and
nozE) and those carrying the PCR-targeted gene mutants (nozA::scar, nozD::scar and
nozE::scar). Synthetic cyclo(L-Trp-L-Trp) served as a control. Depletion of cyclo(L-TrpL-Trp) production in the nozA::scar mutant further confirmed the function of nozA in
cyclo(L-Trp-L-Trp) assembly. No metabolites differed between metabolite profiles from
S. coelicolor M1152 carrying contig 557 and those carrying contig 557 with PCRtargeted gene deletions. Chromatograms show absorbance at 210 nm.
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Conclusions and Future Directions
This thesis study provides insight into the biosynthetic pathway from
Nocardiopsis sp. CMB-M0232 responsible for the catalytic assembly of the
nocardioazines, novel 2,5-DKP natural products particularly interesting due to
their unique chemical structures and the promise of nocardioazine A as an
anticancer agent. Two CDPS homologs identified in the draft genome sequence
of Nocardiopsis were biochemically characterized via in vivo and in vitro methods
to reveal that each catalyzes the production of cyclo(L-Trp-L-Trp), the
hypothesized precursor in the nocardioazine biosynthetic pathway. Evaluation of
the substrate specificity of NozA and NcdA revealed that both CDPSs are
specific for tryptophanyl-tRNA substrates, catalyzing the production of cyclo(LTrp-L-Trp) and no other 2,5-DKPs with alternative aromatic aminoacyl-tRNAs.
This finding renders NozA and NcdA two of only three characterized CDPSs that
are substrate specific, incorporating only one aminoacyl-tRNA substrate.
Furthermore, Nocardiopsis provides a rare example of a single bacterium
encoding two distinct enzymes that catalyze biosynthesis of the same secondary
metabolite. The physiological relevance of DKP-derived natural products is still
largely speculative, as little is known about the actual use of these metabolites in
the native organism. A more thorough understanding of their biological
importance may provide clues as to why Nocardiopsis has evolved to use two
phylogenetically identical enzymes in the biosynthesis of cyclo(L-Trp-L-Trp), a
precursor of the nocardioazines.
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The chromosomal region surrounding nozA contains putative CDPtailoring enzymes with roles predicted in the modifications made to nocardioazine
B to produce nocardioazine A. NozD and NozE, two cytochrome P450 homologs
downstream from nozA were heterologously expressed with NozA in
Streptomyces to determine their involvement in assembly of nocardioazine A.
The approaches employed by this study were not able to confirm the enzymatic
activity of these enzymes, but lead the way toward future studies to optimize the
conditions for probing NozD and NozE activity. In addition, future work will aim to
elucidate the biological properties of the methyltransferase and prenyltransferase
homologs, NozB and NozC, respectively, from contig 119. These enzymes are
also hypothesized to play roles in nocardioazine assembly (Figure 14).
Uncovering their roles in the biosynthesis may link cyclo(L-Trp-L-Trp) produced
by NozA and NcdA with the modified scaffold characteristic of nocardioazine B.
The results gathered from this thesis study have offered novel
cyclodipeptide-synthesizing enzymes, adding to the knowledge of a relatively
understudied class of enzymes that offer novel natural products. The
characterization of NozA and NcdA combined with future work to better
understand the unique engineering of the C3’-prenyl functional group and other
nocardioazine groups by Nocardiopsis may provide new opportunities for
pathway engineering to produce new bioactive drugs.
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Appendix
Appendix A. Sequence of the E. coli optimized nozA gene, optimized and synthesized
by GeneArt (Life Technologies).

nozA
GAATTGGCGGAAGGCCGTCAAGGCCACGTGTCTTGTCCAGAGCTCCATATGCA
TACCGTTAGCGTTGAACGTGATGGTGATTTTCATGTTACACCGCTGACCGATAAT
TGTCGTGATCTGATGAAAGCCGGTGGTCATGCACTGCTGGGTGTTAGCCATGG
TAATAGTTATTTTAGCCGTGGTCGTCTGAGCAACCTGTTTGCATGGGCACTGCG
TCGTTTTGATGCAGTTGATGTTGTTGCAGCAGATAGCCATGTTGTGGAAATTTTT
CGTGCCATTGGCTATGATGATGAACATGCACGTAAACGCACCCATAAAGAAACC
AGCGTTCTGCGTAATCGTATTCGTGATGCAGCAGCACAGTGTGGTGCAGATCG
TACCCGTATTACCCTGCGTGGTCTGAGCGATTTTATGGATGATCCGGCATATCGT
AGCGTTCTGAGCGAAACCCAGAAAGCACTGGATGATCAGCCGGAATTTCGTAA
TGCAGCCCGTGCAATGACCCGTGCAGTTCTGGAAAGCCGTCTGGGTCCGGGT
AATGCACGTGAAGATCAGATTGATATTGCCTTTAGCTATCTGCAGGCAGAACTG
CCGTTTTTTCATGATGCACCGCGTATTCTGCGTGTTGAAAGCACCGTTAGCTGT
TATCACATGCGTCTGCCGCTGCTGGATTTTATCTGTGGTCCGCGTGCAGTTGTT
CCGGTTGTGCCGACCCAGGGTTTTGCCGTTGTTCGTCCGGCAGATCCGGGTA
AGCTTGGTACCTGGAGCACAAGACTGGCCTCATGGGCCTTCCGCTCACTG
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Appendix B. Sequence of the E. coli optimized ncdA gene, optimized and synthesized
by GeneArt (Life Technologies).

ncdA
ATTGGCGGAAGGCCGTCAAGGCCACGTGTCTTGTCCAGAGCTCCATATGAGC
GGTCCGCATGCAGTTCCGGATGGTGGTAGCGCACCGCCTCCGAGCCGTCGTG
CCAGCTTTACCGTTGAACCGTTTACCGATGCATGTCATGCAGTTTGGGAACAGC
GTCGTCATGCCGTTCTGGGTGTTAGTCCGGGTAATGGCTATTTTAACGTTGCAC
TGCTGACCGAACTGCTGGGTTGGGCATGTGGTGAATTTGCACGTGTTGATGTT
GTTGTTCCGGATAGCGCACTGGAACACACCTATCTGGCACTGGGTTATGATCTG
CGTCGTGCAGCAAAAAAAGCACGTGGTGAAACCAATGTTCTGCGTAATCGTGT
TGTTCGTGCATGGGAAGCCGGTGGTGGTCCGCGTGCAAGTGATGGTCTGCAT
CGTATGAGCGAACTGGCAAGCAATGCAGCATATCGTGCAGGTCTGGCAGAATG
TGAACGTGCACTGGGTGAAGATGATCTGCTGTGGGAAACCTGTGCAGAAATGA
GCCGTGATGTTCTGGCAGCCCGTGGTCATGATGGTCCGCTGACCACCGAACG
TGTTGAACGTGCCATGCGTTATCTGACCGCAGAACTGCCGTTTTTTCTGGCAA
GCGCAGATATTTTTGGTGTTCCGAGCAGCCTGAACTTTTATCATCGTCGTCTGC
CGCTGGCAGAAGTTGTTTTTGCAGGTAAAAGCGTTCTGCAGGCACCGCCTGCA
CAGGGTTATGCAACCATTCGTCCGGCAGGTCGTGATCCTGATCGTGCAAAGCT
TGGTACCTGGAGCACAAGACTGGCCTCATGGGCCTTCCGCTCAC
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Appendix C. List of primer sequences used in this study. Regions in bold are FLP
recognition targets.
Primer
1NozA_SDM_F
2NozA_N114A_R
2NozA_N114R_R
2NozA_V111RN114A_R
NozA_L131R_F
NozA_L131R_R
NozA_S36A_F
NozA_S36A_R
NozA_S198L_F
NozA_S198L_R
NozA::scarKO_F
NozA::scarKO_R
NozD::scarKO_F
NozD::scarKO_R
NozE::scarKO_F
NozE::scarKO_R
SuperpSET_F1
SuperpSET_R1
SuperpSET_F2
SuperpSET_R2
NozACnt557_F
NozACnt557_R
NozA_KOCon_F
NozA_KOCon_R
NozD_KOCon_F
NozD_KOCon_R
NozE_KOCon_F
NozE_KOCon_R

Sequence (5' --> 3')
TGATGCAGCAGCACAGTGTGGTGCAG
CGAATACGCGCACGCAGAACGCTGGT
CGAATACGACGACGCAGAACGCTGGT
CGAATACGCGCACGCAGACGGCTGGT
GGCATATCGTAGCGTTCGTAGCGAA
GGATCATCCATAAAATCGCTCAGAC
CACTGCTGGGTGTTGCCCATGGTAA
CATGACCACCGGCTTTCATCAGATC
GTTGAAAGCACCGTTCTGTGTTATCAC
ACGCAGAATACGCGGTGCATCATGAA
GCCCCTCGACGCCGATGATGGGAAGGACAGCCCGTGGTGAT
TCCGGGGATCCGTCGACC
GGGTGCCGGCCCGCAGGCGGGCCGGCGGCCCCTGGATCAT
GTAGGCTGGAGCTGCTTC
GGCCGAAACGCCACGGCCCCCACCGGAGGTTCCCGTTTGAT
TCCGGGGATCCGTCGACC
TGCCGGGCCTCGCTCGGGTCCGGGCGCGGCGGCGGGTCAT
GTAGGCTGGAGCTGCTTC
CCCCGGCGCACAGAGCCGATCCCGACGGGAGACCCCTTGAT
TCCGGGGATCCGTCGACC
TGGGCGCGGGGATCGGGGACCGCCGGGCGCCGGGGTCAT
GTAGGCTGGAGCTGCTTC
CATGATCGTGCTCCTGTCGT
CTACGGAAGGAGCTGTGGAC
TAAATAGCTGCGCCGATGGT
GTATCCTGCGTGATGAGCCA
ACTGCCGTGACCTCATGAAG
TCTCCTACCTCCAAGCCGAA
GCCGTTAACACCAGCTTCAC
GGACCTCTTCCGCCACTATG
ACCAGCCCGAATTCCGAAAT
GTGGCTGATCACCTCCCAC
GGTTCCCCACGATGTACCTG
TGCTGAAGAACCACCTCGTC
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Appendix D. Origin and accession number (NCBI) of biochemically characterized
CDPSs including NozA and NcdA from Nocardiopsis and characterized in this thesis.

CDPS
Amir_4627
YvmC_lic
YvmC_sub
YvmC_thu
Jk0923
Rv2275
Nvec_CDPS2
Ndas_1148
NcdA
NozA
Plu0297
pSHaeC06
AlbC

NCBI accession
number
Origin
Actinosynnema mirum
ACU38460
Bacillus licheniformis
AAU25020
Bacillus subtilis
CAB15512
Bacillus thuringiensis
EAO57133
Corynebacterium jeikeium
CAI37087
Mycobacterium tuberculosis
P9WPF9
Nematostella vectensis
EDO44063
Nocardiopsis dassonvillei
ADH66589
Nocardiopsis sp. CMB-M0232
KT184401
Nocardiopsis sp. CMB-M0232
KT184400
Photorhabdus luminescens laumondii CAE12592
Staphylococcus haemolyticus
BAE05998
Streptomyces noursei
AAN07909

Preferential
products
c(WW)
c(LL)
c(LL)
c(LL)
c(LL)
c(YY)
c(WX)
c(FY)
c(WW)
c(WW)
c(LL)
c(LL)
c(LF)
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Appendix E. 1H NMR (500 MHz, CDCl3) spectra confirming the chemical structure and
purity of nocardioazine A.
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nocardioazine B
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Appendix F. 1H NMR (500 MHz, CDCl3) spectra confirming the chemical structure and
purity of nocardioazine B.
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